MCID: OPD006
MIFTS: 48

Opioid Addiction

Categories: Neuronal diseases

Aliases & Classifications for Opioid Addiction

MalaCards integrated aliases for Opioid Addiction:

Name: Opioid Addiction 25
Opiate Addiction 25 71
Opiate Dependence 25
Opioid Dependence 25

Classifications:



External Ids:

UMLS 71 C0524662

Summaries for Opioid Addiction

Genetics Home Reference : 25 Opioid addiction is a long-lasting (chronic) disease that can cause major health, social, and economic problems. Opioids are a class of drugs that act in the nervous system to produce feelings of pleasure and pain relief. Some opioids are legally prescribed by healthcare providers to manage severe and chronic pain. Commonly prescribed opioids include oxycodone, fentanyl, buprenorphine, methadone, oxymorphone, hydrocodone, codeine, and morphine. Some other opioids, such as heroin, are illegal drugs of abuse. Opioid addiction is characterized by a powerful, compulsive urge to use opioid drugs, even when they are no longer required medically. Opioids have a high potential for causing addiction in some people, even when the medications are prescribed appropriately and taken as directed. Many prescription opioids are misused or diverted to others. Individuals who become addicted may prioritize getting and using these drugs over other activities in their lives, often negatively impacting their professional and personal relationships. It is unknown why some people are more likely to become addicted than others. Opioids change the chemistry of the brain and lead to drug tolerance, which means that over time the dose needs to be increased to achieve the same effect. Taking opioids over a long period of time produces dependence, such that when people stop taking the drug, they have physical and psychological symptoms of withdrawal (such as muscle cramping, diarrhea, and anxiety). Dependence is not the same thing as addiction; although everyone who takes opioids for an extended period will become dependent, only a small percentage also experience the compulsive, continuing need for the drug that characterizes addiction. Opioid addiction can cause life-threatening health problems, including the risk of overdose. Overdose occurs when high doses of opioids cause breathing to slow or stop, leading to unconsciousness and death if the overdose is not treated immediately. Both legal and illegal opioids carry a risk of overdose if a person takes too much of the drug, or if opioids are combined with other drugs (particularly tranquilizers called benzodiazepines).

MalaCards based summary : Opioid Addiction, also known as opiate addiction, is related to opiate dependence and chronic pain. An important gene associated with Opioid Addiction is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Valproic acid and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Opioid Addiction

Diseases related to Opioid Addiction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 opiate dependence 31.2 OPRM1 OPRK1 OPRD1 DRD2
2 chronic pain 31.2 OPRM1 COMT
3 personality disorder 30.8 DRD2 COMT CCK
4 substance abuse 30.6 OPRM1 OPRK1 OPRD1 DRD2 COMT
5 alcohol use disorder 30.5 OPRM1 DRD2 COMT
6 polysubstance abuse 30.5 DRD2 COMT
7 heroin dependence 30.2 OPRM1 OPRD1 DRD2 COMT
8 social phobia 30.0 DRD2 COMT CCK
9 opioid abuse 30.0 PNOC OPRM1 OPRK1 OPRD1 DRD2 CCK
10 withdrawal disorder 30.0 PNOC OPRM1 OPRK1 OPRD1 DRD2
11 cocaine dependence 30.0 OPRM1 OPRK1 OPRD1 DRD2 COMT
12 drug dependence 30.0 PNOC OPRM1 OPRK1 OPRD1 DRD2
13 somatoform disorder 30.0 OPRM1 OPRD1 COMT
14 eating disorder 29.9 OPRM1 DRD2 COMT CCK
15 trigeminal neuralgia 29.9 OPRM1 OPRK1 OPRD1
16 amnestic disorder 29.9 OPRM1 OPRK1 OPRD1 DRD2
17 tobacco addiction 29.8 OPRM1 DRD2 CYP2B6 COMT
18 morphine dependence 29.8 OPRM1 OPRK1 OPRD1 CCK
19 substance dependence 29.8 OPRM1 OPRK1 OPRD1 DRD2 COMT
20 diarrhea 29.8 OPRM1 OPRK1 CCK ABCB1
21 pain agnosia 29.7 PNOC OPRM1 OPRK1 OPRD1 CCK
22 constipation 29.7 OPRM1 OPRK1 OPRD1 CCK
23 obsessive-compulsive disorder 29.5 GRIN2A DRD2 COMT CCK
24 panic disorder 29.5 DRD2 COMT CCKBR CCKAR CCK
25 attention deficit-hyperactivity disorder 29.3 OPRM1 GRIN2A DRD2 COMT ABCB1
26 psychotic disorder 29.3 OPRM1 GRIN2A DRD2 COMT CCK
27 neonatal abstinence syndrome 29.2 PNOC OPRM1 OPRK1 OPRD1 CYP2B6 COMT
28 major depressive disorder 29.0 OPRM1 GRIN2A DRD2 CYP2B6 COMT ABCB1
29 disease of mental health 28.9 OPRM1 OPRK1 OPRD1 GRIN2A DRD2 COMT
30 migraine with or without aura 1 28.8 PNOC OPRM1 OPRK1 OPRD1 DRD2 COMT
31 pertussis 28.8 OPRM1 MAPK3 MAPK1
32 fibromyalgia 28.5 PNOC OPRM1 OPRK1 OPRD1 GRIN2D DRD2
33 anxiety 28.3 PNOC OPRM1 OPRK1 OPRD1 GRIN2A DRD2
34 autism 28.3 OPRM1 MAPK3 GRIN2D GRIN2A DRD2 COMT
35 alcohol dependence 28.3 PNOC OPRM1 OPRK1 OPRD1 GRIN2A DRD2
36 schizophrenia 27.1 OPRM1 GRIN3B GRIN2D GRIN2A DRD2 COMT
37 opioid dependence 1 12.7
38 schizophrenia 5 10.4 DRD2 COMT
39 cocaine abuse 10.3
40 tardive dyskinesia 10.3 DRD2 COMT
41 hallucinogen dependence 10.3 OPRM1 DRD2 COMT
42 avoidant personality disorder 10.3
43 drug psychosis 10.2 DRD2 COMT
44 cannabis abuse 10.2 OPRM1 DRD2 COMT
45 drug-induced mental disorder 10.2 DRD2 COMT
46 trigeminal nerve disease 10.2 OPRM1 OPRK1 OPRD1
47 acalculous cholecystitis 10.2 CCKAR CCK
48 substance-induced psychosis 10.2 DRD2 COMT
49 pedophilia 10.2
50 gastroparesis 10.1 DRD2 CCK ABCB1

Comorbidity relations with Opioid Addiction via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Deficiency Anemia Dysthymic Disorder
Heart Disease Hypertension, Essential
Major Depressive Disorder Osteoporosis

Graphical network of the top 20 diseases related to Opioid Addiction:



Diseases related to Opioid Addiction

Symptoms & Phenotypes for Opioid Addiction

MGI Mouse Phenotypes related to Opioid Addiction:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 ABCB1 CCKAR CCKBR COMT DRD2 GRIN2A
2 homeostasis/metabolism MP:0005376 9.97 ABCB1 CCK CCKAR CCKBR COMT DRD2
3 endocrine/exocrine gland MP:0005379 9.96 ABCB1 CCK CCKAR CCKBR COMT DRD2
4 digestive/alimentary MP:0005381 9.92 ABCB1 CCKAR CCKBR DRD2 MAPK1 MAPK3
5 integument MP:0010771 9.65 CCKBR DRD2 GRIN2A GRIN2D MAPK1 MAPK3
6 nervous system MP:0003631 9.44 ABCB1 CCK CCKAR CCKBR COMT DRD2

Drugs & Therapeutics for Opioid Addiction

Drugs for Opioid Addiction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 281)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
2
Ribavirin Approved Phase 4 36791-04-5 37542
3
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
5
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
6
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
7
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
8
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
9
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
10
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
11
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
12
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
13
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
14
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
15
Tapentadol Approved Phase 4 175591-23-8 9838022
16
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
17
Methadone Approved Phase 4 76-99-3 4095
18
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
19
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
20
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
21
Methadyl Acetate Experimental, Illicit Phase 4 509-74-0 10517
22 GABA Agents Phase 4
23 Cholinergic Agents Phase 4
24 Nicotinic Agonists Phase 4
25 Pharmaceutical Solutions Phase 4
26 Anesthetics, General Phase 4
27 Anesthetics, Intravenous Phase 4
28 interferons Phase 4
29 Interferon alpha-2 Phase 4
30 Interferon-alpha Phase 4
31 Immunologic Factors Phase 4
32 Adjuvants, Anesthesia Phase 4
33 Cytochrome P-450 CYP3A Inducers Phase 4
34 Dopamine agonists Phase 4
35 Ketorolac Tromethamine Phase 4
36 Neurotransmitter Agents Phase 4
37 Adrenergic Agents Phase 4
38 Anti-Infective Agents Phase 4
39 Anesthetics, Local Phase 4
40 Anesthetics Phase 4
41 Excitatory Amino Acid Antagonists Phase 4
42 Excitatory Amino Acids Phase 4
43 Hormones Phase 4
44 Anticonvulsants Phase 4
45 Antimanic Agents Phase 4
46 Anti-Anxiety Agents Phase 4
47 Antibiotics, Antitubercular Phase 4
48 Antitubercular Agents Phase 4
49 Anti-Bacterial Agents Phase 4
50 Antimetabolites Phase 4

Interventional clinical trials:

(showing 502, show less)
# Name Status NCT ID Phase Drugs
1 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
2 SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model Unknown status NCT00241930 Phase 4
3 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
4 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
5 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Treatment in Opioid Dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4 Methadone;Buprenorphine/naloxone
6 Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study) Completed NCT00263458 Phase 4
7 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
8 An Open Multi-center Trial of Suboxone® (Buprenorphine/Naloxone) Treatment Among Opiate-Dependent Subjects Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
9 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
10 VIVITROL® (Naltrexone for Extended Release Injectable Suspension (XR-NTX)) for Opioid Dependent Inmates Released From Prison Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
11 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
12 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
13 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
14 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
15 A Phase 4, Pilot, Open-label Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
16 A Multi-center, Open-Label, 24-Week, Follow-Up Study to Assess Safety, Efficacy, and Treatment Adherence For Maintenance Treatment of Opioid Dependence With OX219 Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
17 Feasibility Study of Take-Home LAAM Medication Completed NCT00000300 Phase 4 LAAM
18 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
19 A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Completed NCT00007527 Phase 4 naloxone;buprenorphine
20 Project STRIDE2 - Seek/Test/Retain: PLWHA and Opioid Users in Washington, DC Completed NCT03583138 Phase 4 buprenorphine
21 A Single Center, Randomized, 2 Way Cross-Over, Phase 4 Study Comparing Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 Including Ease of Use, Taste Preference, Dissolution Time, Desire to Abuse, and Overall Acceptance In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
22 Intensive Outpatient v. Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
23 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
24 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
25 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
26 Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO) Completed NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
27 CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Completed NCT02032433 Phase 4 Extended-Release Naltrexone;Buprenorphine-Naloxone
28 Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients Completed NCT01471145 Phase 4 Naltrexone
29 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
30 Naltrexone: Consummatory Behaviors in Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
31 Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth Completed NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
32 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4 Transdermal nicotine patch
33 Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine: A Four-phase Cross-over Study in Healthy Subjects. Completed NCT01854489 Phase 4 Placebo;Rifampicin;Buprenorphine
34 Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
35 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
36 Pain Control in the Nuss Procedure: A Prospective, Randomized Trial of Cryoanalgesia vs. Thoracic Epidural Completed NCT02721017 Phase 4 Thoracic epidural (ropivicaine, fentanyl)
37 Use of Liposomal Bupivacaine for Postoperative Pain Management After Arthroscopic Rotator Cuff Repair Completed NCT03149887 Phase 4 Liposomal bupivacaine;Placebo
38 Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial Completed NCT02922985 Phase 4 Intravenous acetominophen;Ketorolac, intramuscular;Bupivacaine, subcutaneous;Normal saline
39 A Feasibility Study for Testing the Effects of Extended-release Naltrexone (Vivitrol) on Recidivism and Other Participant Outcomes in Drug Court Settings Completed NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
40 Long Acting Naltrexone for Opioid Addiction: the Importance of Mental, Physical and Societal Factors for Sustained Abstinence and Recovery Recruiting NCT03647774 Phase 4 Extended release naltrexone
41 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
42 Optimizing Patient Centered-Care: A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse (OPTIMA Trial) Recruiting NCT03033732 Phase 4 Methadone;Buprenorphine-Naloxone
43 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
44 Houston Emergency Opioid Engagement System (HEROES) Recruiting NCT03396276 Phase 4 Suboxone
45 A Randomized Clinical Trial of Single Dose Liposomal Bupivacaine Delivered Via VATS Intercostal Nerve Block vs. Continuous Bupivacaine Infusion Delivered Via Indwelling Subscapular Catheter After Surgical Stabilization of Rib Fractures Recruiting NCT03305666 Phase 4 Liposomal bupivacaine injection;Bupivacaine indwelling catheter
46 RCT of Gabapentin Versus Placebo for Postoperative Pain After Sacrospinous Ligament Fixation for Pelvic Organ Prolapse Recruiting NCT03123861 Phase 4 Gabapentin;Placebo oral capsule
47 Safety and Efficacy of Pre-emptive Tapentadol vs Pregabalin in Post Operative Pain Following Unilateral Total Knee Arthroplasty- A Randomised, Double Blind, Active Control, Clinical Trial Recruiting NCT03604354 Phase 4 Tapentadol 100 MG Oral Tablet;Pregabalin 150mg
48 Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery Recruiting NCT03893734 Phase 4 methadone;Hydromorphone
49 Bridging Care to HCV Treatment Among Opiate Dependent Patients on Buprenorphine/Naloxone Maintenance Therapy: A Pilot Study of Treating HCV With Epclusa at a Psychiatrist-staffed Outpatient Addiction Clinic Active, not recruiting NCT03235154 Phase 4 sofosbuvir/velpatasvir
50 Biomarkers of Disease and Response to Treatment in Opioid Addiction Active, not recruiting NCT02324725 Phase 4 Naltrexone
51 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry Active, not recruiting NCT01999946 Phase 4 Extended-Release Naltrexone
52 An Open-Label, Single-Center Study to Evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc at Steady State Following Once-daily Administration of CASSIPA® in Opioid Dependent Subjects. Not yet recruiting NCT04088266 Phase 4
53 Buprenorphine Extended-release in Jail and at Re-entry: Open-label Randomized Controlled Trial vs. Daily Sublingual Buprenorphine-naloxone Not yet recruiting NCT03604159 Phase 4 Buprenorphine Extended Release;Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
54 Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption Not yet recruiting NCT03534102 Phase 4 Improved Opioid-Tapering Instructions
55 Efficacy of Metamizole Versus Ibuprofen and a Short Educational Intervention Versus Standard Care in Acute and Subacute Low Back Pain: A Randomized, Factorial Trial Not yet recruiting NCT04111315 Phase 4 Metamizole Sodium;Ibuprofen 600 mg
56 A Prospective, Sixteen-Week, Double-Blind, Placebo-Controlled, Trial of Seroquel in Combination With Treatment as Usual in Patients With GAD and Remitted Comorbid Opiate Dependence Terminated NCT00668265 Phase 4 Quetiapine
57 A Randomized Controlled Trial Testing Buprenorphine as a Treatment in Opiate Dependent Pain Patients Terminated NCT00552578 Phase 4 buprenorphine/naloxone;buprenorphine/naloxone
58 A Randomized Controlled Trial Comparing Buprenorphine/Naloxone With Naltrexone for Treatment in Opioid Dependent Adolescents and Young Adults Withdrawn NCT01015066 Phase 4 Buprenorphine/naloxone;Naltrexone
59 Smoking Cessation & Opioid Dependence Treatment Integration: Does Timing Matter? Unknown status NCT02854800 Phase 2, Phase 3 varenicline
60 Advances in Opiate Detoxification Using the Combined Hemoperfusion-hemodialysis: A Comparison Study With Conventional Methadone Treatment (HPDMT) Unknown status NCT01021566 Phase 3 Methadone
61 Combined Therapy of Methadone and Dextromethrophan: A Novel Strategy for the Treatment of Opioid Dependence Unknown status NCT01189097 Phase 3 Dextromethorphan;Dextromethorphan
62 Mirtazapine as a Treatment for Co-Occurring Opioid and Amphetamine Type Stimulant Dependence (COATS) in Malaysia Unknown status NCT02541526 Phase 3 Mirtazapine;Placebo
63 An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence Unknown status NCT02541513 Phase 3 paliparidone
64 Maternal Opioid Treatment: Human Experimental Research Completed NCT00271219 Phase 3 Methadone;Buprenorphine
65 Naltrexone Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction - a Randomised Study Completed NCT00521157 Phase 2, Phase 3 Go Medical Naltrexone implants
66 CS1008 A&B Eff/Safety Trial of BUP/NX for the Treatment of Opiate Dependence Completed NCT00015171 Phase 3 Buprenorphine/naloxone
67 Open-Label Study of the Safety and Tolerability of VIVITROL Administered to Health Care Professionals Participating in an Extended Outpatient Treatment Program for Opioid Dependence Completed NCT00834080 Phase 3 Medisorb naltrexone 380 mg
68 Improving Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone (Vivitrol) Before vs. After Reentry Completed NCT02617628 Phase 2, Phase 3 extended release naltrexone
69 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients With Opioid Dependence Completed NCT00447564 Phase 3 Probuphine;placebo
70 A Randomized, Placebo and Active-Controlled, Multi-Center Study of Probuphine in Patients With Opioid Dependence Completed NCT01114308 Phase 3 Probuphine (buprenorphine implant);placebo implant;Buprenorphine
71 Prevention of Relapse to Opioid Addiction Using Depot Naltrexone Completed NCT00781898 Phase 2, Phase 3 Depot naltrexone
72 A Phase 3, Six-Month, Open-Label, Re-Treatment Study of Probuphine in Opioid Addiction Completed NCT01262261 Phase 3 Probuphine (buprenorphine implant)
73 An Open-Label, Multi-Center Extension Study Of Probuphine in Patients With Opioid Dependence Completed NCT00630201 Phase 3 Probuphine (buprenorphine implant)
74 Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults Completed NCT01052662 Phase 2, Phase 3 Memantine;Memantine;Placebo
75 Efficacy and Safety of VIVITROL® (Naltrexone for Extended-release Injectable Suspension) in Adults With Opioid Dependence Completed NCT00678418 Phase 3 VIVITROL® 380 mg;Placebo
76 Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail Completed NCT01180647 Phase 3 Extended-Release Naltrexone
77 Linking Hospitalized Injection Drug Users to Buprenorphine Completed NCT00987961 Phase 3
78 Health Promotion and Public Safety: Community-based Collaborative Services to Addicted Offenders Completed NCT01843751 Phase 3 buprenorphine/naloxone
79 Comparing Opium Tincture (OT) and Methadone for Medication-assisted Treatment of Opioid Use Disorder: A Randomized Double-blind Controlled Clinical Trial Completed NCT02502175 Phase 3 opium;methadone
80 Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules Completed NCT00078117 Phase 3 Buprenorphine
81 Reinforcing Effects of Intranasal Buprenorphine Versus Buprenorphine/Naloxone in Buprenorphine-maintained Intranasal Drug Users Completed NCT01760473 Phase 3 Intranasal challenge drug
82 CSP #1024 - A Phase III, Randomized, Multi-Center, Double Blind, Placebo-Controlled Study of Safety and Efficacy of Lofexidine for Relief of Symptoms in Subjects Undergoing Inpatient Opiate Detoxification. Completed NCT00235729 Phase 3 Lofexidine;Placebo
83 Suboxone and Methadone for HIV Risk Reduction in Subutex Injectors Completed NCT01131273 Phase 3 methadone;buprenorphine-naloxone (Suboxone) for 12 weeks
84 A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal Completed NCT00032942 Phase 3 Lofexidine
85 North American Opiate Medication Initiative (NAOMI): Multi-Centre, Randomized Controlled Trial of Heroin-Assisted Therapy for Treatment-Refractory Injection Opiate Users Completed NCT00175357 Phase 3 Methadone;Diamorphine hydrochloride
86 Bup/Nx - Facilitated Rehab for Opioid Dependent Adolescents Completed NCT00078130 Phase 3 Buprenorphine/naloxone
87 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL Completed NCT02696434 Phase 3 Naltrexone;Placebo;Buprenorphine
88 Psychopharmacotherapy in Multiple Substances Abuse / Dependence - the Pharmacological and Immunological Approach to the New Indication of Memantine Completed NCT01189214 Phase 3 Memantine
89 Distress Tolerance and Reducing Early Relapse in Buprenorphine Patients Completed NCT01556087 Phase 3
90 A Randomized, Blinded, Active-controlled Non-inferiority Study of the Efficacy and Safety of OX219 for the Induction of Treatment of Opioid Dependence Completed NCT01848054 Phase 3 Buprenorphine/naloxone sublingual tablets;Buprenorphine
91 Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal Completed NCT00980044 Phase 2, Phase 3 Tramadol;Placebo
92 A Randomized, Double-Blind, Double-Dummy, Active-Controlled Multicenter Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily Maintenance Dose of 8 mg or Less of Sublingual Buprenorphine or Buprenorphine/Naloxone to Four Probuphine® Subdermal Implants Completed NCT02180659 Phase 3 sublingual buprenorphine tablets;Buprenorphine implant;placebo implants;sublingual placebo tablets
93 Methadone Maintenance & HIV Risk in Ukraine Completed NCT00351026 Phase 3 Methadone
94 Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia Completed NCT01389167 Phase 3 Vivitrol;Naltrexone (oral)
95 Antidepressants During Office-Based Buprenorphine Completed NCT00475878 Phase 3 escitalopram;placebo
96 Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification Completed NCT00032955 Phase 3 Buprenorphine/naloxone
97 Dronabinol Naltrexone Treatment for Opioid Dependence Completed NCT01024335 Phase 2, Phase 3 injectable naltrexone and dronabinol;Naltrexone and placebo
98 Placebo Controlled Study of Memantine as an Adjunct to Naltrexone in the Treatment of Opioid Dependence Completed NCT00476242 Phase 2, Phase 3 Vivitrol;memantine
99 Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial of At-Home Versus In-Office Buprenorphine Induction Completed NCT00684554 Phase 2, Phase 3 Buprenorphine
100 Phase III Study of Maintenance Treatment for Opiate Dependence With Heroin (Diamorphine) Compared to Methadone Completed NCT00268814 Phase 3 Diacetylmorphine;Methadone
101 Treatment for Opioid Dependent Offenders Completed NCT01082679 Phase 2, Phase 3 Methadone;buprenorphine (Suboxone)
102 Reinforcing Effects of Intravenous Buprenorphine Versus Buprenorphine/Naloxone in Buprenorphine-maintained Intravenous Drug Users (P05207) Completed NCT00710385 Phase 3 Heroin;Naloxone;Low Bup Dose;High Bup Dose;Low Bup/Nal Dose;High Bup/Nal Dose;Placebo (PCB)
103 Induction, STabilization, Adherence, and Retention Trial (ISTART) - A Randomized, Non-inferiority, Multicenter Study to Assess Early Treatment Efficacy of OX219 Versus SUBOXONE Film and to Explore Switching Between Treatments Completed NCT01908842 Phase 3 BNX sublingual tablets;BNX sublingual film;Buprenorphine
104 Behavioral Naltrexone Therapy (BNT) for Promoting Adherence to Oral Naltrexone (BNT-oral) vs Extended Release Injectable Depot Naltrexone (Depot-BNT); a Randomized Trial Completed NCT00577408 Phase 3 depot naltrexone;Oral Naltrexone
105 Buprenorphine/Naloxone Versus Clonidine For Out-patient Opiate Detoxification Completed NCT00032968 Phase 3 Buprenorphine/naloxone
106 Pharmacological Treatment of Narcotic Neonatal Withdrawal Completed NCT02810782 Phase 3 Phenobarbital;Chlorpromazine;Morphine
107 HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a Methadone Maintenance Treated (MMT) Opioid Addicted Group. Completed NCT00147784 Phase 3 Ribavirin;Pegylated Interferon
108 A Randomized, Open Label, Long-Term, Multi-Center Study of the Safety of Medisorb® Naltrexone Completed NCT01218997 Phase 3 Medisorb naltrexone 380 mg;Oral naltrexone 50 mg
109 Fetal and Infant Effects of Maternal Buprenorphine Treatment Completed NCT01561079 Phase 2, Phase 3 Buprenorphine
110 Extended Tobacco Dependence Intervention in Buprenorphine Treatment Completed NCT01350011 Phase 3
111 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess the Efficacy, Safety, and Tolerability of Multiple Subcutaneous Injections of Depot Buprenorphine (RBP-6000 [100 mg and 300 mg]) Over 24 Weeks in Treatment-Seeking Subjects With Opioid Use Disorder Completed NCT02357901 Phase 3 SUBOXONE;RBP-6000;Placebo
112 Optimal Prevention of Overdose Deaths and Opioid Relapse Following Discharge: A Multi-Center RCT of Naltrexone Versus Buprenorphine in Norway Completed NCT01717963 Phase 3 Naltrexone intramuscular suspension;Buprenorphine-naloxone
113 Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China Completed NCT00757744 Phase 3
114 A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Standard Medical Management or Enhanced Medical Management for Opioid Analgesic Dependence Completed NCT00316277 Phase 3
115 SALOME: Multi-Centre, Double Blind Randomized Controlled Trial Comparing The Effectiveness Of Diacetylmorphine Vs. Hydromorphone For The Treatment Of Long-Term Injection Opioid Users Who Do Not Benefit From Available Therapies Completed NCT01447212 Phase 3 Hydromorphone, Injectable;Diacetylmorphine, injectable;Hydromorphone, liquid oral;Diacetylmorphine, liquid oral
116 Cocaine Use Reduction With Buprenorphine (CURB) Completed NCT01402492 Phase 2, Phase 3 Buprenorphine + Naltrexone;Placebo + Naltrexone
117 Depot Pharmacotherapies for Opioid-Dependent Offenders: Outcomes and Costs Completed NCT02110264 Phase 3 XR-NTX
118 Behavioral Drug and HIV Risk Reduction Counseling With MMT in China Completed NCT01389180 Phase 3
119 Cognitive Function and Addiction in Patients With Chronic Pain Under Opioid Tapering in a Multidisciplinary Pain Treatment Completed NCT03365817 Phase 3 Opioids taper off;Opioid stable treatment
120 Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone: An Outpatient Detoxification for Opioid Dependence. Completed NCT02294253 Phase 2, Phase 3 Buprenorphine/naloxone
121 Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14) Completed NCT01863186 Phase 3 Lofexidine HCl;Placebo;Open Label Lofexidine HCL
122 Efficacy and Safety of Ketamine Added to Local Anesthetic in Modified Pectoral Block for Management of Postoperative Pain in Patients Undergoing Modified Radical Mastectomy Completed NCT02620371 Phase 3
123 Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence Recruiting NCT02696096 Phase 3 Suboxone
124 The Effectiveness of Deep Brain Stimulation for Opioid Relapse Prevention Recruiting NCT02440152 Phase 2, Phase 3
125 Improving Treatment Outcomes for Prescription Opioid Dependence Recruiting NCT02543944 Phase 2, Phase 3 Gabapentin;Buprenorphine;Clonidine;Naltrexone (oral);Naltrexone (depot);Placebo
126 Glutamatergic Modulation to Facilitate Naltrexone Initiation: A Randomized, Controlled Trial Recruiting NCT03345173 Phase 3 CI-581-a;CI-581-b
127 A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders Recruiting NCT03232346 Phase 3 Vivitrol;Buprenorphine
128 Long-acting Naltrexone for Pre-release Prisoners: A Randomized Trial of Mobile Treatment Recruiting NCT02867124 Phase 3 XR-NTX
129 Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol Recruiting NCT03113409 Phase 2, Phase 3 Buprenorphine;Naltrexone;Vivitrol
130 Effect of Intraoperative and Post-operative Opioids on Persistent Opioid Use in the Surgical Patient Recruiting NCT03367988 Phase 2, Phase 3 Opioid Anesthesia;Opioid-free Anesthesia
131 Bupropion-Enhanced CM for Cocaine Dependence Recruiting NCT02111798 Phase 2, Phase 3 Bupropion XL;placebo
132 Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone Active, not recruiting NCT01882361 Phase 2, Phase 3 injectable naltrexone;placebo comparator
133 An Open-label, Multicentre, Single-arm Trial of Monthly Injections of Depot Buprenorphine in People With Opioid Dependence Active, not recruiting NCT03809143 Phase 3 RBP-6000
134 Lidocaine Infusion for Chronic Pain in Opioid Dependent Patients Active, not recruiting NCT02219321 Phase 3 Lidocaine infusion;Saline infusion
135 The Efficacy of Suvorexant in the Residential Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial Enrolling by invitation NCT03412591 Phase 2, Phase 3 Suvorexant 20 mg
136 The Nicholson Science Pheromone Trial Not yet recruiting NCT03394911 Phase 3
137 A Single Cross-Over, Open-Label Study of the Relative Bioavailability of Probuphine Versus Buprenorphine Sublingual Tablets at Steady State in Patients With Opioid Dependence Terminated NCT00768482 Phase 3 Probuphine (buprenorphine implant);Sublingual Buprenorphine
138 An Open-label, Multi-center Extension Study of Probuphine in Patients With Opioid Dependence Terminated NCT00772785 Phase 3 Probuphine (buprenorphine implant)
139 Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction. Terminated NCT00269607 Phase 2, Phase 3 Implantation of naltrexone implants
140 A Phase III Randomized Controlled Trial to Evaluate the Efficacy of Drug Treatment in Prevention of HIV Infection and Death Among Opiate Dependent Injectors Terminated NCT00270257 Phase 3 Buprenorphine/Naloxone
141 Efficacy of Clonidine in Reducing Iatrogenic-induced Opioid Dependence in Infants: Terminated NCT01360450 Phase 2, Phase 3 Clonidine HCL;saline
142 Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects Withdrawn NCT01713803 Phase 3 Buprenorphine and naloxone
143 Liposomal Bupivacaine in Ambulatory Hand Surgery Withdrawn NCT02933814 Phase 3 Liposomal Bupivicaine
144 A Randomized, Double-blind, Active Control Evaluation of the Safety of BioErodible MucoAdhesive (BEMA®) Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects Withdrawn NCT02516436 Phase 3 BEMA Buprenorphine NX;Buprenorphine
145 Clinical Trial of Integrated Treatment for Pain and Opioid Dependence Unknown status NCT00634803 Phase 1, Phase 2 Buprenorphine
146 Science-Based Treatment for Opioid-Dependent Adolescents Unknown status NCT00182572 Phase 2 buprenorphine;naltrexone
147 Facilitating MAT Acceptance & Implementation in Problem Solving & Felony Courts Unknown status NCT03229447 Phase 1, Phase 2
148 A Stage 1 Study of Community Reinforcement and Family Training for Treatment Drug Abuse Treatment Retention/HIV Risk Reduction Unknown status NCT00609089 Phase 1, Phase 2
149 Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia Unknown status NCT00539123 Phase 2
150 Cell Phone Technology Targeting ART Adherence and Drug Use Unknown status NCT01884233 Phase 2
151 An Examination of the Efficacy, Safety, and Gender Differences in Using Varenicline as an Aid to Smoking Cessation in a Population of Methadone Maintained Opioid Dependent Patients (Pilot Trial) Unknown status NCT00906386 Phase 2 Varenicline;placebo
152 Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study Unknown status NCT02249026 Phase 1, Phase 2 BZDs + opiate exposure treated with BPN;Opiates exposure treated with BPN
153 Trial of Buprenorphine/Naloxone for Treatment of Opiate Dependence Completed NCT00000344 Phase 2 Buprenorphine/naloxone
154 Withdrawal Suppression Efficacy of Tramadol Completed NCT00142896 Phase 2 Tramadol;Naloxone;Morphine
155 Lofexidine: Enhancing Naltrexone Treatment for Opiate Addiction Completed NCT00142909 Phase 2 Lofexidine;Placebo
156 CS1008A Efficacy/Safety Trial of Buprenorphine/Naloxone Completed NCT00015028 Phase 2 Buprenorphine/naloxone
157 Testosterone Replacement for Male Opioid Agonist Maintained Patients Completed NCT01873989 Phase 1, Phase 2 Testosterone replacement
158 Buprenorphine Effectiveness Evaluation in HIV Enhancement (BEEHIVE): A Randomized Trial of HIV Clinic-based Buprenorphine/Naloxone vs. Case Management and Referral in Opioid-dependent Individuals Completed NCT00130819 Phase 2
159 An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects (BNX-201) Completed NCT01666119 Phase 2 BEMA Buprenorphine NX films
160 Buprenorphine Maintenance for Opiate Dependence Completed NCT00000357 Phase 2 Buprenorphine
161 Efficacy/Safety Trial of Buprenorphine/Nx for Opiate Dependence Completed NCT00000353 Phase 2 Buprenorphine/naloxone
162 Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia Completed NCT01863251 Phase 2 Atomoxetine
163 Evaluation of NMDA Antagonist for Opiate Dependence Completed NCT00125515 Phase 2 Memantine;Naltrexone
164 Disulfiram for Cocaine Abuse in Buprenorphine Treatment Completed NCT00913484 Phase 2 Disulfiram;Placebo
165 Assessment of the Level of Physical Dependence and Blockade Efficacy Produced by Tramadol Completed NCT00301210 Phase 1, Phase 2 Tramadol
166 Place of Low-Dose Naltrexone in Opiate Detoxification Completed NCT00135759 Phase 2 Naltrexone;Placebo comparator;naltrexone;naltrexone
167 Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence Completed NCT00548275 Phase 2
168 Pharmacokinetics of LAAM in Methadone Patients Completed NCT00000356 Phase 2 LAAM
169 Buprenorphine Maintenance for Opioid-Addicted Persons in Jail and Post-Release Completed NCT00367302 Phase 1, Phase 2 buprenorphine;methadone
170 Evaluation of Opioid Antagonist Activity in Humans Completed NCT00460239 Phase 2 Buprenorphine;Morphine;Placebo
171 An Open Label, Flexible Dose Study of Very Low Doses of Naltrexone-Buprenorphine Transfer to Extend-Release Naltrexone (VIVITROL®) in Opioid Addiction Completed NCT01690546 Phase 2 very low dose naltrexone;extended release naltrexone;buprenorphine/naloxone
172 Clinical Efficacy and Serum Proteomic Profiling of Traditional Chinese Medicine, Suan-Zao-Ren Tang, for Sleep Disturbance During Methadone Maintenance: Study Protocol for a Randomized, Double-blind, Placebo-controlled Trial Completed NCT01913418 Phase 2 Suan-Zao-Ren Tang;Suan-Zao-Ren Tang placebo
173 Study Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence Completed NCT00332228 Phase 2 depot naltrexone;BNT
174 Medications Development for Drug Abuse Disorders Completed NCT00499746 Phase 1, Phase 2 tramadol;placebo;Hydromorphone;Methylphenidate
175 Tiagabine for the Treatment of Cocaine Dependence in Methadone-Maintained Individuals Completed NCT00129298 Phase 2 Tiagabine
176 Opioid Maintenance Medications Comparison Study Completed NCT00344812 Phase 2 LAAM. buprenorphine and methadone
177 Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients Completed NCT00000352 Phase 2 Dextromethorphan
178 Buprenorphine Maintenance for Opioid Addicts Completed NCT00000203 Phase 2 Buprenorphine
179 Acute Effects of Cortisol on Heroin Craving in Opioid Dependence Completed NCT01718964 Phase 2 Cortisol 20 mg;Mannitol
180 Brief Introductory Therapy for Opioid Dependence Completed NCT00406484 Phase 2
181 Treatment Efficacy for Drug Abuse and AIDS Prevention Completed NCT00000210 Phase 2 Buprenorphine
182 Yoga for Pain and Opioid Dependence Completed NCT01590251 Phase 1, Phase 2
183 Opiate Dependence: Combined Naltrexone/Behavior Therapy Completed NCT00238914 Phase 2 Naltrexone
184 Pharmacokinetics and Bioavailability of Liquid vs Tablet Buprenorphine Completed NCT00000341 Phase 2 Buprenorphine
185 Buprenorphine Maintenance Dose Schedule and Treatment Setting: Pilot Completed NCT00000318 Phase 2 Buprenorphine
186 Employment-Based Depot Naltrexone Clinical Trial Completed NCT00684788 Phase 2
187 Activity Monitoring Assessment of Opiate Withdrawal Completed NCT00000335 Phase 2 Morphine
188 Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence Completed NCT02437344 Phase 2 CI-581aa;Naltrexone titration and XR-NTX initiation
189 Naltrexone Implants Compared to Methadone Maintenance Treatment (MMT) Among Inmates About to be Released From Prison - a Randomized Controlled Trial Completed NCT00204243 Phase 2 Naltrexone;Methadone
190 Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution Completed NCT00000320 Phase 1, Phase 2 Buprenorphine formulation: liquid vs. tablet
191 Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals Completed NCT01262092 Phase 2 Buprenorphine
192 A Randomized, Single-Dose Opiate Challenge Study of Medisorb® Naltrexone in Opioid-Using Adults Completed NCT01218984 Phase 2 Medisorb naltrexone 75 mg;Medisorb naltrexone 150 mg;Medisorb naltrexone 300 mg;Hydromorphone (10 mg/mL);Naloxone Challenge and Oral Naltrexone Tolerability Testing
193 Dose Reduction Strategies in Oral Opioid Dependence Subsequent to Pain Management: An Exploratory Study Completed NCT00218101 Phase 2 Buprenorphine
194 Dextroamphetamine as an Adjunct in Cocaine/Opiate Dependent Patients Completed NCT00000306 Phase 2 Dextroamphetamine
195 D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals Completed NCT00780442 Phase 2 D-cycloserine;Placebo
196 Transdermal Electroacupuncture for Opioid Detoxification Completed NCT00742170 Phase 1, Phase 2
197 Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone Completed NCT00637000 Phase 2 Buprenorphine soluble film;Buprenorphine/naloxone film strip;Placebo
198 Employment-Based Depot Naltrexone Clinical Trial II Completed NCT00684775 Phase 2
199 Interim Buprenorphine: Leveraging Medication + Technology to Bridge Delays in Treatment Access Completed NCT02360007 Phase 1, Phase 2 Interim Buprenorphine Treatment (IBT)
200 Oxytocin Treatment of Opioid Dependence Completed NCT02548728 Phase 1, Phase 2 Intranasal Oxytocin Spray;Placebo
201 Cannabidiol as Treatment Intervention for Opioid Relapse Completed NCT01605539 Phase 2 Cannabidiol 400;Cannabidiol 800;Control
202 Hyperalgesia in Methadone-Maintained Patients: Can it be Treated? Completed NCT01210079 Phase 2 Gabapentin;;Placebo
203 Improving Buprenorphine Detoxification Outcomes With Isradipine Completed NCT01895270 Phase 1, Phase 2 Isradipine;Placebo
204 Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations Completed NCT01246401 Phase 1, Phase 2 Extended-Release Naltrexone
205 A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals Completed NCT01136356 Phase 1, Phase 2 buprenorphine;morphine
206 Effective Treatment for Prescription Opioid Abuse Completed NCT00719095 Phase 2 buprenorphine taper followed by naltrexone maintenance
207 To Characterize the Acute and Short-term Effects of Cannabidiol (CBD) Administration on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans Completed NCT02539823 Phase 2 CBD 400 mg;CBD 800 mg;Control (placebo)
208 Extended-Release Naltrexone (XR-NTX, VIVITROL) for the Treatment of Actively-Using Methamphetamine-Dependent Men Who Have Sex With Men Completed NCT01449565 Phase 2 Naltrexone;Placebo
209 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Alcohol Dependence Completed NCT00210925 Phase 2 topiramate
210 A Randomized, Double-blind, Placebo-controlled, Dose of RBP-8000 Following IV Cocaine to Evaluate the Pharmacokinetics Parameters of RBP-8000 and Cocaine and to Assess the Effects of Drug on Cocaine-induced Physiologic and Behavioral Effects in Cocaine Abusing Subjects Completed NCT01846481 Phase 2 RBP-8000 100 mg;Placebo;Cocaine;RBP-8000 200 mg
211 Nalrexone Facilitated Discontinuation of Buprenorphine Completed NCT01895036 Phase 1, Phase 2 Naltrexone
212 Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine Completed NCT02263248 Phase 1, Phase 2 venlafaxine;buprenorphine;placebo
213 A Phase 2 Multi-Center Open-label Study to Assess the Safety and Tolerability of a Buprenorphine/Naloxone Film Strip Administered by the Sublingual and Buccal Routes Completed NCT00640835 Phase 2 Buprenorphine/naloxone Film Strip;Buprenorphine/naloxone Film Strip
214 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse Completed NCT01967641 Phase 2 buprenorphine/naloxone combination
215 The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence Completed NCT01556425 Phase 2 Vivitrol
216 CRAFT Behavior Therapy Phase 2 Study: Treatment Entry Component Completed NCT00842036 Phase 2
217 HIV Risk Reduction and Drug Abuse Treatment in Malaysia Completed NCT00383045 Phase 2 Buprenorphine/Subutex;Naltrexone
218 Mechanisms of Mindfulness Meditation, Cognitive Therapy, and Mindfulness-Based Cognitive Therapy for Low Back Pain Completed NCT02478307 Phase 1, Phase 2
219 A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With REL-1017 25 mg Daily and 50 mg Daily as Adjunctive Therapy in the Treatment of Patients Diagnosed With Major Depressive Disorder Completed NCT03051256 Phase 2 REL-1017;Placebo
220 Effectiveness of Disulfiram for Treating Cocaine Dependence in Individuals With Different Dopamine Beta Hydroxylase (DBH) Genes Completed NCT00149630 Phase 2 Disulfiram;Methadone
221 Disulfiram for Cocaine Abuse Completed NCT00395850 Phase 2 Disulfiram
222 Incentive-based Smoking Cessation for Methadone Patients Completed NCT00718835 Phase 2
223 A Randomized, Double-blind, Double-dummy, Active-drug-controlled, Parallel-group, Multicentre Acceptability and Safety Study of the Transfer From Subutex/Suboxone to RBP-6300 in Opioid-dependent Subjects Completed NCT01582347 Phase 2 RBP-6300;Subutex®/Suboxone®;Placebo for RBP-6300;Placebo for Subutex®/Suboxone®
224 Levetiracetam (Keppra) Treatment for Cocaine Dependence in Methadone-Maintained Patients Completed NCT00577005 Phase 2 levetiracetam;Placebo
225 Pharmacotherapy & CM for Opioid and Cocaine Dependence Completed NCT00838981 Phase 1, Phase 2 Modafinil;Sugar Pill;Methadone
226 Adherence to HIV Therapy in Heroin Addicts: Oral vs. Extended Release Naltrexone Completed NCT01101815 Phase 2 Oral Naltrexone;Naltrexone Implant
227 Open-Label, Multicenter, Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, Efficacy Markers, and Opioid Receptor Availability of Subcutaneous Injections of Depot Buprenorphine in Treatment Seeking Opioid-Dependent Subjects Completed NCT01738503 Phase 2 RBP-6000;Subutex
228 Randomized, Proof-Of-Concept Trial of Augmentation of Antidepressants by Low Dose Naltrexone (LDN) for Patients With Breakthrough Symptoms of Major Depressive Disorder on Antidepressant Therapy Completed NCT01874951 Phase 2 Naltrexone;Placebo
229 Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine Completed NCT02181231 Phase 1, Phase 2 venlafaxine XR;buprenorphine;Placebo
230 Oral Naloxone for Treatment of Opioid-induced Constipation in Patients Receiving Methadone Maintenance Treatment Completed NCT02137213 Phase 2 Naloxone;Placebo
231 Remote Observed Dosing of Suboxone to Improve Clinical Practice Recruiting NCT03769025 Phase 1, Phase 2
232 Buprenorphine Treatment for Prescription Opioid Dependence Recruiting NCT02187198 Phase 1, Phase 2 Buprenorphine
233 Buprenorphine Treatment at Syringe Exchanges to Reduce Opioid Misuse and HIV Risk Recruiting NCT03150173 Phase 2 Buprenorphine
234 Pharmacologically-based Strategies for Buprenorphine Treatment During Pregnancy Recruiting NCT03831113 Phase 2 Buprenorphine: Magnitude Group;Buprenorphine: Frequency Group;Buprenorphine: Dosing Group
235 Randomized Controlled Trial of Repeat vs. Single Quadratus Lumborum Block to Reduce Opioid Prescriptions After Open Pancreatectomy ("RESQU-BLOCK" Trial) Recruiting NCT03745794 Phase 2 Quadratus Lumborum Block
236 Medical Management of Sleep Disturbance During Opioid Tapering Recruiting NCT03789214 Phase 2 Placebo oral capsule;Low Dose Suvorexant;High Dose Suvorexant
237 Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation Recruiting NCT03420313 Phase 2 Buprenorphine/naloxone sublingual tablets
238 Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children Recruiting NCT03447782 Phase 1, Phase 2 Naltrexone HCl (Bulk) Powder
239 High Dosage Buprenorphine as a Drug Strategy Withdrawal Assistance of Analgesics Opioid After Failure of an Opioid Tapering-off Strategy. Recruiting NCT03156907 Phase 2 Buprenorphine/naloxone
240 A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase Ⅱb Clinical Trial of Thienorphine Hydrochloride Tablets for the Efficacy, Safety, and Optimal Dosing of Relapse Prevention After Opioid Dependence Detoxification Not yet recruiting NCT03656120 Phase 2 0.2mg group;0.5mg group;placebo control group
241 Nanoencapsulated Cannabidiol Time Released Capsules Targeted to Reduce Cravings in the Treatment of Opioid Addiction Not yet recruiting NCT03813095 Phase 2 APH-1501;Placebo
242 A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy of Ketamine for the Treatment of Concurrent Opioid Use Disorder and Major Depressive Disorder Not yet recruiting NCT04177706 Phase 2 Ketamine Hydrochloride;Placebo
243 Placebo-Controlled Evaluation of the Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use Terminated NCT00430573 Phase 2 D-cycloserine;Placebo
244 Abuse Potential of Buprenorphine/Naloxone as a Function of Maintenance Dose of Buprenorphine/Naloxone Terminated NCT00149539 Phase 2 Buprenorphine/naloxone
245 Safety and Efficacy of Pre-incisional Intravenous Ibuprofen to Reduce Postoperative Pain and Opioid Dependence After Posterior Cervical or Lumbar Instrumented Spine Surgery Terminated NCT02276911 Phase 2 Ibuprofen
246 The Variability of Agonist and Antagonist Effects as a Function of Level of Physical Dependence Terminated NCT00142727 Phase 2 Methadone;Full opioid agonist;Partial opioid agonist;Opioid antagonist
247 Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants Terminated NCT02935101 Phase 2 Prednisolone;Placebo (for Prednisolone)
248 Neurobiology of Opioid Dependence: 5 Withdrawn NCT00000196 Phase 2 Naltrexone
249 Neurobiology of Opioid Dependence: 3 Withdrawn NCT00000194 Phase 2 Cycloserine
250 Neurobiology of Opioid Dependence: 2 Withdrawn NCT00000193 Phase 2 Gamma hydroxybutyric
251 Neurobiology of Opioid Dependence: 1 Withdrawn NCT00000192 Phase 2 Lamotrigine
252 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 Withdrawn NCT00000331 Phase 2 Test Drug;Placebo Drug
253 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 Withdrawn NCT00000330 Phase 2 Opioid-Related Disorders
254 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 Withdrawn NCT00000329 Phase 2 Opioid-Related Disorders
255 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III Withdrawn NCT00000328 Phase 2 Opioid-Related Disorders
256 Neurobiology of Opioid Dependence: 4 Withdrawn NCT00000195 Phase 2 Naltrexone
257 HIV Risk Reduction and Drug Abuse Treatment in Iran Withdrawn NCT00398008 Phase 2 Buprenorphine/Subutex;Naltrexone
258 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1(1) Withdrawn NCT00000326 Phase 2 Heroin Dependence
259 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) Withdrawn NCT00000327 Phase 2 Heroin Dependence
260 Oxytocin in Opiate Dependence: A Double-blind, Within-subjects, Placebo-controlled Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence Unknown status NCT02052258 Phase 1 Oxytocin
261 A Phase 1 Study to Evaluate the Relative Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction Completed NCT02801357 Phase 1 lofexidine administration in subjects seeking buprenorphine dose reduction
262 Comparison of Cognitive-Behavioral Therapy and Methadone Drug Counseling for Methadone-Maintained Patients With Co-occurring Chronic Pain and Opioid Dependence Completed NCT01334580 Phase 1
263 Clinical Laboratory Evaluations of Aprepitant for the Treatment of Opioid Dependence: Inpatient Test Completed NCT01527994 Phase 1 Aprepitant;Placebo pill
264 Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution Completed NCT01560221 Phase 1 Methadone;Buprenorphine
265 Effects of Buprenophine and Naloxone in Opiate Addicts Completed NCT00000355 Phase 1 Buprenorphine
266 Safety Evaluation of Lofexidine for Treatment of Opioid Withdrawal Completed NCT00000354 Phase 1 Lofexidine
267 A Pivotal, Phase 1, Open-Label, Randomized, Crossover, Single-Dose, Comparative Bioavailability Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers Completed NCT02477267 Phase 1 SL spray;SL film
268 Evaluation of Lofexidine for Treatment of Opiate Withdrawal Completed NCT00000345 Phase 1 Lofexidine
269 Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse Completed NCT00292123 Phase 1 Methadone
270 A Phase-I, Two-Stage, Double-Blind, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Trial of Low Doses of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects. Completed NCT00829777 Phase 1 6β-Naltrexol escalating doses from 0.05-0.5 mg IV
271 The Role of Varenicline in Treating Opioid Dependence: A Pilot Study Completed NCT01436474 Phase 1 Varenicline;Placebo
272 Drug Discrimination in Methadone-Maintained Humans Study 2 Completed NCT00733239 Phase 1 2-4 of the drugs listed below
273 PK 0396 - Buprenorphine Dose Escalation Trial Completed NCT00015041 Phase 1 Buprenorphine
274 Acceptance Therapy During Methadone Detoxification Completed NCT00439036 Phase 1
275 A Phase 1, Open-Label, 2-Period Drug Interaction Study to Assess Steady State Plasma Methadone Enantiomer Pharmacokinetics Following Co-Administration of Methadone QD With Dolutegravir (GSK1349572) 50 mg Twice Daily in Opiate-Dependent, HIV Seronegative Adult Subjects. Completed NCT01467518 Phase 1 Dolutegravir;Methadone
276 Drug Discrimination in Methadone-Maintained Humans Study 3 Completed NCT01068847 Phase 1 2-4 of the drugs listed below
277 A Phase 1, Open-Label, Single-Sequence Study to Examine the Effect of Telaprevir on the Pharmacokinetics of Buprenorphine in Subjects on Stable Buprenorphine/Naloxone Maintenance Therapy Completed NCT01275599 Phase 1 telaprevir;buprenorphine/naloxone
278 Drug Discrimination in Methadone-Maintained Humans Study 1 Completed NCT00593463 Phase 1 Cycloserine;Diltiazem;Gabapentin;Isradipine;Naloxone;Nifedipine;Placebo;Verapamil
279 Mindfulness-Oriented Recovery Enhancement for Chronic Pain Patients Receiving Opioid Therapy: Exploration of Cognitive, Affective, and Physiological Mechanisms Completed NCT01505101 Phase 1
280 Cannabidiol as Treatment Intervention for Opioid Relapse Completed NCT01311778 Phase 1 Cannabidiol;Fentanyl
281 Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications Completed NCT00877591 Phase 1 Fosamprenavir/Ritonavir;Darunavir/Ritonavir;Rifampin;Rifabutin;Buprenorphine
282 Long-acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone vs. Buprenorphine Completed NCT01377610 Phase 1 oral naltrexone;Buprenorphine;Vivitrol
283 Analgesic Effects and Abuse Liability of Intravenous Hydromorphone and Buprenorphine in Pain-free Opioid Dependent Participants Completed NCT01642030 Phase 1 Placebo;Hydromorphone;Buprenorphine
284 Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients Completed NCT00295308 Phase 1 Clonidine;Placebo
285 Medication-Assisted Treatment for Youth With Substance Use Disorders Completed NCT02593474 Phase 1 Naltrexone
286 Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients Completed NCT00780702 Phase 1 Airipiprazole;Placebo
287 A Pilot, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Electrocardiographic Effects of Lofexidine When Administered Orally to Methadone Maintained Adult Subjects Completed NCT01558934 Phase 1 Lofexidine HCl
288 A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Electrocardiographic Effects of Lofexidine When Administered Orally to Methadone Maintained Adult Subjects Completed NCT01650649 Phase 1 Lofexidine HCl;Lofexidine-matching sugar pill
289 A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Electrocardiographic Effects of Lofexidine When Administered Orally to Buprenorphine-Maintained Adult Subjects Completed NCT01820442 Phase 1 Lofexidine HCl;Lofexidine-matching sugar pill
290 Biobehavioral Studies of Opioid Seeking: Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence Recruiting NCT03015246 Phase 1 Buprenorphine-Naloxone;Morphine;Yohimbine;Hydrocortisone;Matching Placebo for Yohimbine;Matching Placebo for Hydrocortisone
291 A Pilot Pharmacokinetic (PK) Trial of the O'Neil Long Acting Naltrexone Implant Recruiting NCT03810495 Phase 1 naltrexone implant
292 Towards Predicting the Analgesic Response to Ibuprofen Following Third-molar Extraction Recruiting NCT03893175 Phase 1 Ibuprofen;Acetaminophen;Placebo;Oxycodone
293 Prospective Single-Arm Pilot Study for CT-Guided, Temporary Celiac Ganglion Block as a Test Before Celiac Ganglion Resection for Dysautonomia-Related Bowel Dysmotility Recruiting NCT04121338 Phase 1 Liposomal bupivacaine
294 Pioglitazone as an Aid During Buprenorphine Taper Terminated NCT01517165 Phase 1 Pioglitazone;Placebo
295 Postoperative Ibuprofen Use and Risk of Bleeding in Pediatric Tonsillectomy Withdrawn NCT03385057 Phase 1 Ibuprofen;Acetaminophen
296 Deep Brain Stimulation of Nucleus Accumbens as a New Treatment to Prevent Relapse for Opiate Addicts Unknown status NCT01274988
297 Satisfaction With Care and Quality of Life in Subjects With Substance Dependence Unknown status NCT02894476
298 A Pilot Study to Determine the Genetic Biomarkers Predictive of the Development of Prescription Opioid Addiction in Patients Treated for Pain Using a Comparative Transcriptomic Analysis of Gene Expression in Peripheral Blood Cells Unknown status NCT01562353
299 PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction Unknown status NCT02282072 Early Phase 1
300 Validation of a Pediatric Abstinence Syndrome Scoring Tool Utilizing a Standardized Hospital-Based Guideline for Iatrogenic Opioid Dependence Unknown status NCT00792415
301 Methadone Maintenance Treatment Outcome Study in Taiwan Unknown status NCT01093248
302 Deep Brain Stimulation of the Nucleus Accumbens as a Novel Treatment in Severe Opioid Addiction Unknown status NCT01245075 Early Phase 1
303 Ultra-rapid Opiate Detoxification Using Deep Sedation and Prior Oral Buprenorphine Preparation. Unknown status NCT01008072
304 Executive Functioning in Heroin Users Following a Mobile Health Cognitive Stimulation Approach: a Randomized Controlled Trial Unknown status NCT02308878
305 HIV, Buprenorphine, and the Criminal Justice System Unknown status NCT01550341 Buprenorphine/naloxone
306 An Assessment of Fentanyl Dose Requirements in Opioid-maintained Individuals Unknown status NCT01358500 Fentanyl
307 Attitudes of Patients With Opioid-Substitution and Their Therapists Towards and Buprenorphine and Methadone Unknown status NCT00911846
308 Brain Imaging Study on the Effects of Treatment With Naltrexone on Cue-induced Craving and Brain's Metabolic Changes in Alcohol and Cannabis-dependent Patients Unknown status NCT01560013 Naltrexone
309 QTc and Perceived Sleep Follow up Among Chronic Pain Patients With Opiate Medication Unknown status NCT00999440 Methadone
310 Applying Web Technology to Buprenorphine Treatment Unknown status NCT00182598
311 Pilot Study of Combined Treatment for Veterans With Chronic Pain & Opiate Misuse Unknown status NCT02423772
312 Effect of Slow Injection of Fentanyl on the Incidence of Spinal Anesthesia Induced Itching in Cesarean Section Unknown status NCT02951806 (R) Rapid spinal fentanyl injection;(S) Slow spinal fentanyl injection
313 Efficacy of Acupuncture as an Adjunct to Methadone Treatment Services for Heroin Addicts Unknown status NCT03012373
314 Activity Monitors for Opioid Dependence Treated With Probuphine Unknown status NCT02896660
315 Clinician-patient Interaction During Addiction Consultation and Drug Overdose Risk Unknown status NCT01769651
316 Effects of Buprenorphine/Naloxone in Non-Dependent Opioid Abusers Completed NCT00158236 Buprenorphine;Buprenorphine and Naloxone;Hydromorphone
317 Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir) Completed NCT00571961 Kaletra (lopinavir/ritonavir);buprenorphine
318 Evaluation of Pharmacy Students' Perception of Opioid / Opiate Dependence: Cross-sectional National Study Completed NCT03859778
319 Hepatitis C Education for Pregnant Women With Opiate Addiction - Phase 1 Completed NCT03245931
320 Feasibility and Validity of Using a Novel Artificial Intelligence Platform to Monitor and Optimize Medication Adherence in Patients Receiving Opioid Replacement Therapy Completed NCT02243670
321 Miami Buprenorphine HIV Care Integration Project Completed NCT00348868
322 Evaluation of Dialectical Behavior Therapy (DBT) Completed NCT00117741
323 Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Completed NCT00134914 Buprenorphine
324 Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence Completed NCT02602795
325 Addition of Contingency Management to Stop Smoking Services for Patients Undergoing Treatment for Opiate Addiction: a Randomised Controlled Pilot Study Completed NCT03015597
326 The Effect of Valproate Treatment on Withdrawal Severity in Benzodiazepine Dependent Opioid Maintenance Treatment Patients Completed NCT00570219 valproate
327 Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department Completed NCT00913770 Buprenorphine Initiation
328 Serotonin Treatment of Cocaine Dependence Completed NCT00142779 Fluoxetine
329 Project BEST: Buprenorphine Entry Into Substance Abuse Treatment Completed NCT02583243 Buprenorphine
330 Evaluation of Dialectical Behavior Therapy in Treatment of Opioid Addiction and Emotional Problems Completed NCT00218595
331 Efficacy of Computer Delivered CRA (Bup II) Grant No. R01DA012997-10 Completed NCT00929253 Suboxone
332 Hyperalgesia in Methadone Patients: Can it be Treated? Completed NCT00218374 Gabapentin
333 Optimizing Outcomes Using Suboxone for Opiate Dependence Completed NCT00591617
334 Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance Completed NCT00622596
335 Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts Completed NCT01668706
336 A Prospective Observational Clinical Trial to Compare the Effect of Immediate Postpartum Nexplanon Placement Versus Standard Postpartum Contraceptive Care on Consistent Contraceptive Use and Rapid Repeat Pregnancy in Opioid Dependent Women. Completed NCT02657148 Nexplanon (etonogestrel contraceptive implant);Standard postpartum contraceptive care
337 Neonatal and Maternal Effects of Buprenorphine and Methadone in the Treatment of Opioid-Maintained Pregnant Women: A Retrospective Cohort Study Completed NCT03024736
338 Remote Observed Dosing to Increase Suboxone Compliance Completed NCT01779973
339 Using mHealth to Aid Opioid Medication Adherence Focus Groups Completed NCT01955902
340 Pilot Study to Investigate the Feasibility and Tolerability of the Use of NSS-2-BRIDGE Device for Post-Operative Pain in Total Knee and Total Hip Arthroplasties Completed NCT03834142
341 An Open-Label Application of the NSS-Bridge Device for Post-Cesarean Pain Completed NCT03830307
342 Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence Completed NCT02496403
343 Hepatitis C Education for Pregnant Women With Opiate Dependence - Phase 2 Completed NCT03320889
344 Electronic Compliance Monitoring in Opioid Substitution Treatment Completed NCT01182402
345 Medicinal Dependence and Chronic Pain: Addictive Evaluation in CETD Completed NCT03635346
346 COMT Val158Met Polymorphism in Opiate-using Subjects Without Lifetime Opiate Dependence Completed NCT01570699
347 Buprenorphine for Treatment of Opioid Dependence in Primary Care Completed NCT00471042 Buprenorphine
348 Breastfeeding Among Methadone Maintained Women Completed NCT00218010
349 A Naturalistic Study of Adolescents and Young Adults in Treatment for Opioid Dependence Completed NCT02718352
350 VIvitrol's Cost and Treatment Outcomes RegistrY Completed NCT01422837
351 Depot Naltrexone Treatment of Opioid Dependent Parolees Completed NCT00756990 Depot Naltrexone
352 Reengineering Methadone Treatment: A Randomized Clinical Trial Completed NCT01442493
353 Transitions: Linkages From Jail to Community Completed NCT00841711
354 Chronic Pain and Opioid Dependence Assessment and Treatment Completed NCT00727675
355 Etude Observationnelle Prospective de l'Utilisation en Situation Reelle; Prospective Real Situation Observational Study of Subutex® or Its Buprenorphine High Dose Generic (BHD) in the Replacement Treatment of Major Opiate Dependence: Following Parameters With Respect to Misuse and Pharmacovigilance Completed NCT00723697 buprenorphine
356 PHAST: Influence of Exercise Training on Substance Use, Substance Craving, Quality of Life, Mental Health, Sleep, and Physical Health in Patients Suffering From Opiate Dependence While Under Substitution Therapy Completed NCT02309021
357 CBT for Depression & Adherence in HIV Methadone Patients Completed NCT00218634
358 A Prenatal Mentalization-focused 4D Ultrasound and a Pregnancy Diary Intervention for Substance-abusing Women Completed NCT03413631
359 The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism With Naltrexone and Sedation Completed NCT02362256 Naltrexone;Clonidine;Lorazepam
360 Using mHealth to Aid Opioid Medication Adherence Pilot Study Completed NCT02017041
361 The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment Completed NCT00857350
362 Methadone Monitoring for Insights Into Adverse Events Completed NCT01191242
363 A Multicenter Study Assessing the Prevalence of Co-addictions in Subjects Receiving Maintenance Treatment for Opiate Dependence. Determination of Clinical and Pharmacological Profil. Completed NCT01847729
364 Bone Density and Serum Testosterone in Male Methadone Maintained Patients Completed NCT00170339
365 Development of a Community-based Buprenorphine Treatment Intervention Completed NCT01761110
366 Treatment-as-Usual Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With NIDA CTN-0051 Completed NCT02730403
367 Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users Completed NCT01108679
368 Entry Into Comprehensive Methadone Treatment Via Interim Maintenance Completed NCT00712036
369 Mobile Phone Messaging to Support Smoking Cessation Among Office-based Buprenorphine and Inpatient Detoxification Patients: a Pilot Study Completed NCT02665208 Nicotine Replacement Therapies
370 GABA-B Receptor Function in Healthy Volunteers: a Pilot, Double Blind Crossover Study of the Effects of 2 Doses of Baclofen and Placebo on Objective and Subjective Measurements of Brain Function Completed NCT01563224 Baclofen 10mg;Baclofen 60mg;placebo
371 Examination of Cognitive Function, Weight, Sexual Function in Patients Receiving Treatment With Subutex at 3 Months Without Using Opiates Completed NCT00687089
372 Neuropsychoanalytic Treatment of Failed Back Surgery Syndrome-Opioid Dependence Completed NCT01940588
373 The Acute and Protracted Blockade Efficacy of Buprenorphine/Naloxone Completed NCT00134888 Buprenorphine/naloxone
374 The Clinical Efficacy of Acupuncture as an Adjunct to Methadone Treatment Services for Heroin Addicts: A Randomized Controlled Trial Completed NCT01512433
375 FAVOR Opioid Recovery Coaching Evaluation Completed NCT03798470
376 Stress, Distress Intolerance, and Drug Dependence Completed NCT00430482
377 A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment Completed NCT01416584
378 Maternal Buprenorphine Administration and Fetal/Infant Neurobehavior Completed NCT00218621
379 Biobehavioral Studies of Opioid Drug Seeking Behavior: Study 1 Completed NCT00218309 Hydromorphone
380 Mindfulness-Based Relapse Prevention for Methadone Maintenance: A Feasibility Trial Completed NCT03882125
381 CATS-CARE: Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis Completed NCT03048643
382 Feasibility and Acceptability of Using an Automated Text Messaging Program to Help Prevent Early Relapse Among Treatment-seeking Opioid Dependent Patients Discharged From the Emergency Department Completed NCT02846649
383 Completion of Substitution Treatment With Methadone/Levomethadone - a Prospective Study Completed NCT01722435 Opiate Substitution Treatment
384 Directly Observed Therapy for Community-Released HIV+ Prisoners Completed NCT00786396
385 A Randomized Trial of an Abstinence-reinforcing Contingency Management Intervention to Suppress HIV Viral Load Completed NCT01376570
386 A Therapeutic Workplace for Drug Abusers Completed NCT00249457
387 SPNS - An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Abuse Treatment in HIV Primary Care Completed NCT00227357 On-site - buprenorphine/naloxone (Suboxone);Off-site - methadone or no agonist
388 Remission From Chronic Opioid Use: Studying Environmental and SocioEconomic Factors on Recovery—The RECOVER Study® Completed NCT03604861
389 Comparing Interventions for Opioid Dependent Patients Presenting in Medical Emergency Departments Completed NCT02586896
390 A Pilot Study of Prolonged, Intermittent Exposure to Alfentanil on Opioid-Induced Hyperalgesia in Healthy Volunteers Completed NCT00991809 Alfentanil;Diphenhydramine
391 Efficacy Evaluation of Traditional Chinese Medicine JITAI Combined Comprehensive Model Among Heroin Addicts After Detoxification Completed NCT01580163 JITAI Combined with psychological intervention;Methadone;Traditional Chinese Medicine JITAI
392 Auricular Percutaneous Electrical Nerve Field Stimulation for Postoperative Pain Control in Adults Completed NCT02892513
393 Prevalence and Predictors of Prolonged Post-surgical Opioid Use: a Prospective Observational Cohort Study Completed NCT02571400
394 The Effects of Minocycline on Opioid-induced Hyperalgesia in Opioid-Maintained Patients Completed NCT02359006 Minocycline;Placebo
395 New Neural Drug Targets: An Evaluation of the Effects of Aprepitant on the Response to Oxycodone Completed NCT00999544 Aprepitant 0mg;Aprepitant 40mg;Aprepitant 200mg;Oxycodone 0mg, p.o.;Oxycodone 20mg, p.o.;Oxycodone 40mg, p.o.;Oxycodone 0mg, IN;Oxycodone 15mg, IN;Oxycodone 30mg, IN
396 Opioid Analgesic Use and Disposal Following Outpatient Dental Surgery Completed NCT02814305
397 The Maternal Lifestyle Study Completed NCT00059540
398 Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks Completed NCT02224508
399 Neural Mechanistic Explanations for Differential Drug Abuse Treatment Outcomes Completed NCT01678833
400 Effectiveness of Contingency Management in VA Addictions Treatment Completed NCT00252512
401 Automated Recovery Line for Medication Assisted Treatment Completed NCT02124980
402 Dopamine D2/3- and μ-opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity in Healthy Volunteers Completed NCT02557984 Placebo;Amisulpride;Naltrexone
403 Life Stories for Opioid Risk Reduction in the ED Completed NCT03134092
404 START Follow-up Study (NIDA CTN Protocol 0050) Completed NCT01592461
405 Measuring Healthcare Professional Students Knowledge and Attitudes Towards Chronic Pain Management. Completed NCT03522857
406 Project RESPECT-Plus: Recovery, Empowerment, Social Services, Prenatal Care, Education and Community Treatment-Plus Completed NCT02334111
407 Packaging Pre-Exposure Prophylaxis (PrEP) to Prevent HIV Transmission Among Women Who Inject Drugs Completed NCT03304912
408 Preemptive Tapentadol on Post-operative Analgesia Following Total Knee Arthroplasty: A Randomized Double Blind Placebo-controlled Trial. Completed NCT03351517 Tapentadol 100 MG;Placebo Oral Tablet
409 Biobehavioral Studies of Opioid Seeking Behavior: Yohimbine and Hydrocortisone Effects Completed NCT01536925
410 The Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans Completed NCT02225184
411 The Expanded HIV Care in Opioid Substitution Treatment (EHOST) Stepped-wedge, Cluster-randomized Trial Completed NCT02440256
412 NIDA-CTN-0044: Web-delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders Using the Therapeutic Education System (TES) Completed NCT01104805
413 Development and Efficacy Test of Computerized Treatment for Marijuana Dependence Completed NCT00594659
414 Pilot Study of Yoga vs. Health Education for Chronic Pain in Persons Receiving Opioid Agonist Therapy Completed NCT03022890
415 Intra-operative Ketamine Infusions in Patients With Chronic Lower Back Discomfort Undergoing Laminectomies. Completed NCT00899600 Ketamine
416 Influence of KCNH2 Polymorphisms on the QTc Interval in Kelantanese Malays Patients Receiving Methadone Maintenance Therapy (MMT) in Malaysia Completed NCT03603158
417 "Auricular Acupuncture and Cognitive Behavioral Therapy in the Context of Insomnia and Low Dose Dependence of Benzodiazepine-like Drugs and Other Sleep Medicine With Addiction Risk" Completed NCT01765959
418 The Effect of Naloxone and Mehtylnaltrexone on Esophageal Sensitivity in Healthy Volunteers: a Randomized, Double-blind, Placebo-controlled Study Completed NCT03014843 Naloxone;Methylnaltrexone Bromide
419 Employment-Based Addiction Pharmacotherapy Completed NCT00149669
420 Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients Completed NCT01645033
421 The Therapeutic Workplace Initiation Study Completed NCT00249470
422 Computer-based Prescription Opioid Abuse Prevention for Adolescents Completed NCT02737696
423 Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET Recruiting NCT03527485
424 Deep Brain Stimulation of Nucleus Accumbens for Opioid Relapse Prevention:A Multicenter Randomized Double-Blind Sham-stimulation Controlled Clinical Trial Recruiting NCT03424616
425 Implementation to Motivate Physician Response to Opioid Dependence in HIV Settings Recruiting NCT03175640
426 Increasing Patient Knowledge of the Signs of Opioid Overdose and Naloxone in a Suburban Treatment Program Recruiting NCT02120612
427 Impact of Pregnancy on Buprenorphine Pharmacokinetics and Pharmacodynamics Recruiting NCT02863601
428 A Pilot Study Investigating the Post-Operative Analgesic Effect of NSS-2 BRIDGE Device in Subjects Undergoing Major Abdominal Oncologic Surgery: A Double-Blind, Randomized, Placebo-Controlled Trial Recruiting NCT03555266
429 Impact of On-site Evaluation of Substances Consumption on Opiate Maintenance in the Context of Family Practice Recruiting NCT02345655
430 Advancing STOP: Self-regulation Therapy for Opioid Addiction and Pain Recruiting NCT03363243
431 Behavioral Treatment Development for Co-occurring Opioid Dependence and Anxiety Disorders Recruiting NCT02252068
432 Medication Adherence Therapy - Psychosocial Leverage Using a Treatment Significant Other Recruiting NCT03567356
433 Effectiveness of Buprenorphine/Naloxone in Patients With Chronic Pain and Iatrogenic Opioid Dependence Recruiting NCT02882412
434 Observational, Prospective Study to Evaluate Levomethadone Safety Profile and Effectiveness in Subjects Under Opioid Maintenance Treatment Recruiting NCT03685162
435 The Impact of Methadone Maintenance Therapy on Food Intake and Food Reward Processing in Opioid Dependence: An Event-related Brain Potential Study Recruiting NCT03575273
436 Evaluating The Efficacy Of A Mind-Body Intervention In Overcoming Opioid Addiction, In Adults Undergoing Opioid Addiction Treatment Recruiting NCT03791645
437 Can The Bridge Facilitate Successful Transition From Medication-Assisted Treatment (MAT) With Low-dose Sublingual Buprenorphine to Oral Naltrexone in Patients With Extended Remission of Opiate Use Disorder Recruiting NCT03762798
438 Behavioral Interventions for Active Duty Service Members and Veterans With Chronic Pain Conditions and Opioid Related Problems Recruiting NCT02935621
439 Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain Recruiting NCT03947749
440 the Efficacy of Electro-acupuncture Therapy for Patients With Methadone Maintenance Treatment : a Randomized Control Trial Recruiting NCT03881618
441 Youth Opioid Recovery Support (YORS): Improving Care Systems for Young Adults With Opioid Use Disorder Recruiting NCT04015115
442 Treatment for Opiate Addiction: Prognostic fActors of Responsiveness to Maintenance Treatment Recruiting NCT03729388
443 DRIVE (DRug Use and Infections in ViEtnam) Project : Ending the HIV Epidemic Among Persons Who Inject Drugs in Hai Phong, Viet Nam Recruiting NCT03526939
444 Naloxone to TReatment Entry in the Emergency Setting Recruiting NCT03368794
445 Feasibility Study to Determine the Effect of Meditation on Perioperative Pain and Distress in Newly Diagnosed Breast Cancer Patients Recruiting NCT04049214
446 tDCS to Decrease Opioid Relapse Recruiting NCT03842137
447 Pilot for Improved Office Based Treatment of Opioid-Dependence Recruiting NCT03586466 Buprenorphine/naloxone
448 Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC): Reducing Tobacco Use Among Opioid Addicted Women Recruiting NCT03796208
449 Deep Brain Stimulation of the Bilateral Nucleus Accumbens for Patients With Methadone Maintenance Treatment Recruiting NCT03952455
450 A Double-Blind, Randomized, Controlled Trial, Utilizing Accelerated Repetitive Transcranial Magnetic Stimulation (rTMS) as a Tool to Decrease Pain and Craving in Hospitalized Patients With Opiate Use Disorder Recruiting NCT03538444
451 Developing Brain Stimulation as a Treatment for Pain in Opiate Dependent Individuals: Parametric Assessment of 2 Evidence-based Strategies Recruiting NCT03576781 Early Phase 1
452 Mindfulness for Pain Recruiting NCT03495726
453 Transcutaneous Electrical Nerve Stimulation and Maternal Opioid Use After Cesarean Delivery Recruiting NCT03843788
454 Pharmacogenetics and Pharmacokinetics of Oxycodone to Personalize Postoperative Pain Management Following Major Inpatient Surgery in Children Recruiting NCT03495388
455 Neuromodulation and Cognitive Training in Opioid Use Disorder Recruiting NCT03773523
456 Addressing Origins of the Opioid Epidemic by Improving Prescribing for Opioid-Naive Patients Recruiting NCT03377855
457 Evaluation of the Efficacy and Mechanisms of a Novel Intervention for Chronic Pain Tailored to People Living With HIV Recruiting NCT03692611
458 Assessment of the Satisfaction of Patient Undergoing Opioid Replacement Therapy Toward Their Management in Community Pharmacy - SATISFY: a Cross-sectional Study Recruiting NCT03961789
459 Evaluating the Utility of a Brief Computerized Anxiety Sensitivity Intervention for Opioid Use Disorders: A Pilot Investigation Recruiting NCT03944850
460 Re-entry XR-NTX for Rural Women With Opioid Use Disorder Recruiting NCT03447743 Early Phase 1 XR-NTX community location
461 A Sleep Intervention to Improve Rehabilitation in Veterans With Chronic mTBI Recruiting NCT03785600
462 An Exploratory Investigation Utilizing Repetitive Transcranial Magnetic Stimulation (rTMS) as a Tool to Decrease Pain and Improve Functioning in Veterans With Opioid Use Disorder Recruiting NCT03821337
463 Electrophysiological Predictors and Indicators of Contingency Management Treatment Response Recruiting NCT03799341
464 University of Houston Drug Abuse Research Development Program II Recruiting NCT03557632
465 A Randomized, Prospective Investigation of a Brief, Daily Mindfulness Intervention for Postoperative Bariatric Patients Recruiting NCT04167852
466 SMS (Short Messaging Service) Education for Post-operative Pain Recruiting NCT04039191
467 Preventing Injection: An mHealth Intervention That Leverages Social Networks to Prevent Progression to Injection Among Young Opioid Users Recruiting NCT03610672
468 Youth Opioid Recovery Support: A Developmentally-specific Intervention for Home Delivery of Extended Release Naltrexone Active, not recruiting NCT03306368
469 A Pilot Randomized Comparative Effectiveness Clinical Trial of Buprenorphine vs. Methadone for the Treatment of Opioid Dependence in Pregnancy. Active, not recruiting NCT03098407 Buprenorphine;Methadone
470 Caffeine and Neurologic Recovery Following Surgery and General Anesthesia Active, not recruiting NCT03577730 Early Phase 1 Caffeine Citrate;Dextrose Water
471 Integrated Treatment of Hepatitis C Virus Infection Among Patients With Injecting Drug Abuse:a Randomised Controlled Trial (INTRO-HCV) Active, not recruiting NCT03155906
472 Life Pain Specialists (LPS) With a Focus on Patient Pain Management and Prevention of Substance Misuse Enrolling by invitation NCT04154384
473 Neuroimaging Response Inhibition and Salience Attribution Changes During Mindfulness-based Treatment of Human Heroin Addiction Not yet recruiting NCT04112186
474 The Effect of Auriculotherapy Combined With an Interscalene Block for Post- Operative Pain Management Following Rotator Cuff Surgery: A Randomized, Placebo-Controlled Trial Not yet recruiting NCT03860259
475 Collaborative Care for Opioid Dependence And Pain Pilot Study Not yet recruiting NCT04121546
476 Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder Not yet recruiting NCT03804619
477 Utilizing Helpline for Opioid Dependence Treatment Not yet recruiting NCT03969238
478 Needle-X: Usability Testing of a Smartphone Application Not yet recruiting NCT03665298
479 A Randomized Clinical Trial of Comprehensive Cognitive Behavioral Therapy (CBT) Via reSET-O for a Hub and Spoke Medication Assisted Treatment (MAT) System of Care. Not yet recruiting NCT04129580
480 Enhancing Analgesia With Non-Deceptive Placebos: A Proof-Of-Concept Pilot Study Not yet recruiting NCT03631251 Early Phase 1 Open Placebo
481 Acupuncture for Relieving Chronic Pelvic Pain Not yet recruiting NCT03854188
482 Evaluation of Liposomal Bipivicaine in Split Thickness Skin Graft Donor Sites in Burn Patients Not yet recruiting NCT03705637 Early Phase 1 Exparel
483 Expanding PrEP Implementation in Communities of People Who Inject Drugs and Their Risk Network Members Not yet recruiting NCT04193787
484 Effect of Multimodal Patient Education With a Personalized 3D Printed Model in Patients With Severe Periarticular Ankle Fractures Not yet recruiting NCT04009252
485 A Prospective Randomized Study Analyzing Preoperative Opioid Counseling in Pain Management After Reduction Mammoplasty Not yet recruiting NCT03985358
486 Administration of Rectal Acetaminophen During Oocyte Retrievals Reduces Post-Operative Opioid Utilization in Fertility Patients Not yet recruiting NCT03732469 Acetaminophen;Fentanyl;Propofol
487 Effectiveness of the Consult for Addiction Treatment and Care in Hospitals (CATCH) Model for Engaging Patients in Opioid Use Disorder Treatment: Pragmatic Trial in a Large Municipal Hospital System Not yet recruiting NCT03611335
488 VERDICT (Veterans Response to Dosage in Chiropractic Therapy): A Pragmatic Randomized Trial Addressing Dose Effects for Chronic Low Back Pain Not yet recruiting NCT04087291
489 A Randomized, Parallel Design Study to Assess the Effectiveness of Patient Registry Directed Patient Navigation in Improving Attainment of Hepatitis C Virus (HCV) Care Management and Treatment Outcomes Among Two HCV Antibody Positive Sub-populations, Patients Using Opioid Substitution Therapy and Patients Who Currently Inject Drugs Not yet recruiting NCT03441542
490 Transitioning Patients From Methadone to Buprenorphine/Naloxone for Treating Opioid Dependence Terminated NCT00000243 Buprenorphine
491 Buprenorphine Tx:A Safe Alternative for Opioid Dependent Pain Patients Terminated NCT01841931 Buprenorphine/Naloxone
492 Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers Terminated NCT00134875 Buprenorphine/naloxone
493 A Randomized Controlled Trial of Auricular Acupuncture to Facilitate Outpatient Opioid Weaning Terminated NCT02882048
494 The Effects of Opioid Taper on Opioid-Induced Hyperalgesia Terminated NCT03063905 Buprenorphine
495 BUPrenorphine Facilitated Access and Supportive Treatment--AIM 3 Terminated NCT02902835
496 A Blinded, Randomized Controlled Trial of Opioid Analgesics for the Management of Acute Fracture Pain in Adults Discharged From the Emergency Department Terminated NCT03478423 Codeine;Oxycodone;Hydromorphone
497 Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol). Withdrawn NCT00675532
498 The Safety and Tolerability of Methadone/Naloxone Combination in Opioid Substitution Treatment Withdrawn NCT01160432 Methadone, naloxone
499 Compliance Monitoring in Real Time During Opioid Substitution Treatment Withdrawn NCT01183130
500 Comparison of Transversus Abdominis Plane Block Versus Patient-controlled Epidural Analgesia for Patients on Buprenorphine or Methadone, After Cesarean Section Withdrawn NCT02091297 TAP Block;Ropivacaine;Acetaminophen;Morphine
501 Effects of Noninvasive Brain Stimulation Methods (rTMS and tDCS) Treatment on Brain Function, Craving and Relapse Prevention Withdrawn NCT03549065
502 A Pilot Study to Evaluate the Feasibility of Mobile Monitoring of Vital Signs in Opioid Users Withdrawn NCT02647073

Search NIH Clinical Center for Opioid Addiction

Genetic Tests for Opioid Addiction

Anatomical Context for Opioid Addiction

MalaCards organs/tissues related to Opioid Addiction:

40
Brain, Testes, Cortex, Liver, Heart, Prefrontal Cortex, Amygdala

Publications for Opioid Addiction

Articles related to Opioid Addiction:

(showing 1903, show less)
# Title Authors PMID Year
1
Enhanced Recovery After Surgery (ERAS): A Perspective Review of Postoperative Pain Management Under ERAS Pathways and Its Role on Opioid Crisis in the United States. 61
31868759 2020
2
Kidney stones and the opioid epidemic: recent developments and review of the literature. 61
31834080 2020
3
Hispanics, Addictions, and the Opioid Epidemic: Brief Report. 61
31747797 2020
4
Nursing Education in the Midst of the Opioid Crisis. 61
31358464 2020
5
Double dissociation of inhibitory effects between the hippocampal TET1 and TET3 in the acquisition of morphine self-administration in rats. 61
32031744 2020
6
Cannabis Use Motivations among Adults Prescribed Opioids for Pain versus Opioid Addiction. 61
31375419 2020
7
Opioid versus opioid-free analgesia after surgical discharge: protocol for a systematic review and meta-analysis. 61
32014880 2020
8
Glial neuroimmune signaling in opioid reward. 61
31790721 2020
9
The effect of Clinical Practice Guidelines on prescribing practice in mental health: A systematic review. 61
31732189 2020
10
Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. 61
31810594 2020
11
D1- but not D2-like dopamine receptor antagonist in the CA1 region of the hippocampus reduced stress-induced reinstatement in extinguished morphine-conditioning place preference in the food-deprived rats. 61
32040018 2020
12
Trends in Mental Well-Being of Non-Hispanic White Children of Midlife Parents With Low Education. 61
31976358 2020
13
The Benefits of Opioid Free Anesthesia and the Precautions Necessary When Employing It. 61
31712783 2020
14
A call for consensus in defining efficacy in clinical trials for opioid addiction: combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder. 61
31907000 2020
15
An Ultra-Brief Mindfulness-Based Intervention for Patients in Treatment for Opioid Addiction with Buprenorphine: A Primary Care Feasibility Pilot Study. 61
31825240 2020
16
Epigenetic Mechanisms of Opioid Addiction. 61
31477236 2020
17
Neurobiology of Opioid Addiction: Opponent Process, Hyperkatifeia, and Negative Reinforcement. 61
31400808 2020
18
Preventing Morphine Seeking Behavior through the Re-engineering of Vincamine's Biological Activity. 61
31913038 2020
19
Opioid crisis: Placing blame or fixing the problem. 61
31913211 2020
20
Pain management strategies in penile implantation. 61
31464206 2020
21
Effects of oxycodone on sensitivity to reinforcement magnitude: implications for effects of opioids on impulsive and risky choice. 61
31922965 2020
22
Non-medical use of loperamide in the UK and the USA. 61
31424512 2020
23
Implications of Drug Use Disorders on Spine Surgery. 61
31926361 2020
24
Views of Rural US Adults About Health and Economic Concerns. 61
31913496 2020
25
Prefrontal GABA and glutamate levels correlate with impulsivity and cognitive function of prescription opioid addicts: A 1 H-magnetic resonance spectroscopy study. 61
31599080 2020
26
Understanding Opioid Use Disorder (OUD) using tree-based classifiers. 61
31962227 2020
27
Effects of social exclusion and physical pain in chronic opioid maintenance treatment: fMRI correlates. 61
30497842 2019
28
Barriers and Facilitators to Intraoperative Alternatives to Opioids: Examining CRNA Perspectives and Practices. 61
31920199 2019
29
Ethics of Opioid Prescriber Regulations: Physicians, Patients, and Pain. 61
31800432 2019
30
Variation on the CRH Gene Determines the Different Performance of Opioid Addicts and Healthy Controls in the IOWA Gambling Task. 61
31805553 2019
31
Inhibition of naltrexone on relapse in methamphetamine self-administration and conditioned place preference in rats. 61
31542477 2019
32
Adopting Graduate Competencies in Opioid Prescribing for Massachusetts Physician Assistant Programs: A Statewide Public Health Response. 61
31664008 2019
33
Provider perceptions of system-level opioid prescribing and addiction treatment policies. 61
30856591 2019
34
Computational framework for predictive PBPK-PD-Tox simulations of opioids and antidotes. 61
31396799 2019
35
A patient-centered approach to tapering opioids. 61
31860698 2019
36
Too few doctors prepared to provide opioid addiction treatment in the north. 61
31844028 2019
37
Physical exercise modifies behavioral and molecular parameters related to opioid addiction regardless of training time. 61
31899030 2019
38
Opioid Addiction Stigma: The Intersection of Race, Social Class, and Gender. 61
31868067 2019
39
Poor Access to Opioid Addiction Care for Total Joint Arthroplasty Patients. 61
31785137 2019
40
Vortioxetine use may cause false positive immunoassay results for urine methadone. 61
31469980 2019
41
The role of the gut microbiome in opioid use. 61
31895059 2019
42
Opioid addiction and the cerebellum. 61
31526817 2019
43
On the early life origins of vulnerability to opioid addiction. 61
31822817 2019
44
Adjunctive memantine for opioid use disorder treatment: A systematic review. 61
31757263 2019
45
Parental morphine exposure affects repetitive grooming actions and marble burying behavior in the offspring: Potential relevance for obsessive-compulsive like behavior. 61
31693870 2019
46
Computational Markers of Risky Decision-making for Identification of Temporal Windows of Vulnerability to Opioid Use in a Real-world Clinical Setting. 61
31812982 2019
47
Orexin-1 Receptor Signaling in Ventral Pallidum Regulates Motivation for the Opioid Remifentanil. 61
31641055 2019
48
Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder. 61
31743739 2019
49
Heroin Cue-Evoked Astrocytic Structural Plasticity at Nucleus Accumbens Synapses Inhibits Heroin Seeking. 61
31495448 2019
50
Machine learning: assessing neurovascular signals in the prefrontal cortex with non-invasive bimodal electro-optical neuroimaging in opiate addiction. 61
31797878 2019
51
Holistic approach to opioid use disorder: Think nitric oxide! 61
31873938 2019
52
Preventing opioid prescription after major surgery: a scoping review of opioid-free analgesia. 61
31563269 2019
53
Pain management in opioid maintenance treatment. 61
31418602 2019
54
Ghrelin receptor antagonism of fentanyl-induced conditioned place preference, intravenous self-administration, and dopamine release in the nucleus accumbens in rats. 61
31696597 2019
55
Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom). 61
30547698 2019
56
Evolution of opioid addiction as a brain disease from stigma to modern neurosciences. 61
31762407 2019
57
Randomized clinical trial comparing buprenorphine/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction. 61
31774028 2019
58
Genetic Variant in the CRH-binding Protein Gene (CRHBP) is Associated With Cessation of Cocaine Use in Methadone Maintenance Patients With Opioid Addiction. 61
30844877 2019
59
Long-term mortality in mothers of infants with neonatal abstinence syndrome: A population-based parallel-cohort study in England and Ontario, Canada. 61
31770382 2019
60
Effects of voluntary exercise and sex on multiply-triggered heroin reinstatement in male and female rats. 61
31712970 2019
61
Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment. 61
31413139 2019
62
Murine model of OPRM1 A118G alters oxycodone self-administration and locomotor activation, but not conditioned place preference. 61
31778689 2019
63
Specificity of personality relationships to particular forms of concurrent substance use among methadone maintenance therapy clients. 61
31351326 2019
64
Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As A Function of Ethnicity: Relevance to Precision Addiction Medicine. 61
31744450 2019
65
Wooden chest syndrome: Beware of opioid antagonists, not just agonists. 61
31831344 2019
66
Methadone serum concentrations and influencing factors: A naturalistic observational study. 61
31139877 2019
67
Chemogenetic modulation of accumbens direct or indirect pathways bidirectionally alters reinstatement of heroin-seeking in high- but not low-risk rats. 61
31747681 2019
68
Sustained-release Oral Hydromorphone for the Treatment of Opioid Use Disorder. 61
31658114 2019
69
Ibogaine Consumption With Seizure-Like Episodes, QTc-Prolongation, and Captured Cardiac Dysrhythmias. 61
31630892 2019
70
Ethics of Opioid Prescriber Regulations: Physicians, Patients, and Pain. 61
31596806 2019
71
Effectiveness of opiate substitution treatment in reducing HIV risk behaviors among African, Caribbean and black people: a systematic review protocol. 61
31634212 2019
72
Current status of opioid addiction treatment and related preclinical research. 61
31616793 2019
73
Effects of craving on opioid use are attenuated after pain coping counseling in adults with chronic pain and prescription opioid addiction. 61
31556668 2019
74
Urine is superior to oral fluid for detecting buprenorphine compliance in patients undergoing treatment for opioid addiction. 61
31394416 2019
75
Adolescent nicotine challenge promotes the future vulnerability to opioid addiction: Involvement of lateral paragigantocellularis neurons. 61
31445026 2019
76
Associations Between the Specialty of Opioid Prescribers and Opioid Addiction, Misuse, and Overdose Outcomes. 61
31626295 2019
77
Stemming the Tide of Opioid Addiction-Dramatic Reductions in Postoperative Opioid Requirements Through Preoperative Education and a Standardized Analgesic Regimen. 61
31621868 2019
78
Outcome of Patients With High Depressive Symptoms on Admission to Methadone Maintenance Treatment. 61
31530109 2019
79
2Hz-electroacupuncture attenuates heroin-seeking behaviors via adjusts CB1-Rs and CB2-Rs expression in relapse-relevant brain regions of heroin self-administration rats. 61
31424247 2019
80
The role of orexin-1 receptor signaling in demand for the opioid fentanyl. 61
31112988 2019
81
Who is HOT and who is LOT? Detailed characterization of prescription opioid-induced changes in behavior between 129P3/J and 129S1/SvlmJ mouse substrains. 61
31489753 2019
82
Opioids and their endocrine effects: A systematic review and meta-analysis. 61
31511863 2019
83
Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. 61
29949228 2019
84
Monitoring opioid addiction and treatment: Do you know if your population is engaged? 61
31302412 2019
85
Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review. 61
31480739 2019
86
Unravelling the mystery of opioid addiction. 61
31511669 2019
87
What Orthopaedic Surgeons Need to Know: The Basic Science Behind Opioids. 61
30676516 2019
88
Clinicians' Guide to Cannabidiol and Hemp Oils. 61
31447137 2019
89
Discovery of Anticancer Clinical Candidate, Tosedostat, As an Analgesic Agent. 61
31415151 2019
90
Cell-type and region-specific nucleus accumbens AMPAR plasticity associated with morphine reward, reinstatement, and spontaneous withdrawal. 61
31201496 2019
91
Multi-level predictors of psychological problems among methadone maintenance treatment patients in difference types of settings in Vietnam. 61
31533764 2019
92
Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. 61
31478285 2019
93
Oral prescription opioid-seeking behavior in male and female mice. 61
31489746 2019
94
Escalated Oxycodone Self-Administration Causes Differential Striatal mRNA Expression of FGFs and IEGs Following Abstinence-Associated Incubation of Oxycodone Craving. 61
31351142 2019
95
A novel role for the actin-binding protein drebrin in regulating opiate addiction. 61
31515501 2019
96
Biosynthesis of an Anti-Addiction Agent from the Iboga Plant. 61
31364847 2019
97
Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography-tandem mass spectrometry. 61
30997725 2019
98
Effect of New York State Electronic Prescribing Mandate on Opioid Prescribing Patterns. 61
31256931 2019
99
Sociodemographic Characteristics and the Stigmatization of Prescription Opioid Addiction. 61
31385847 2019
100
Dietary Supplementation with Omega-3 Polyunsaturated Fatty Acids Reduces Opioid-Seeking Behaviors and Alters the Gut Microbiome. 61
31416242 2019
101
Low-dose naltrexone: a novel adjunctive treatment in symptomatic alopecias? 61
31553867 2019
102
Parental morphine exposure enhances morphine (but not methamphetamine) preference and increases monoamine oxidase-B level in the nucleus accumbens. 61
30694818 2019
103
A Novel Technique to Reduce Reliance on Opioids for Analgesia from Acute Appendicitis: The Ultrasound-guided Erector Spinae Plane Block. 61
31403099 2019
104
Supporting Physicians and Practice Teams in Efforts to Address the Opioid Epidemic. 61
31405881 2019
105
Moving opioid misuse prevention upstream: A pilot study of community pharmacists screening for opioid misuse risk. 61
30031696 2019
106
Kratom policy: The challenge of balancing therapeutic potential with public safety. 61
31103778 2019
107
Heroin seeking becomes dependent on dorsal striatal dopaminergic mechanisms and can be decreased by N-acetylcysteine. 61
29514413 2019
108
Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects. 61
30555159 2019
109
Opioids Use and Abuse: Prescription Practice, Attitude, and Beliefs among Doctors of Karachi. 61
31572638 2019
110
Combating opioid addiction and abuse-2 ways to effectively intervene in the cycle of addiction through pharmacogenomics. 61
31126828 2019
111
A population health perspective on America's opioid addiction. 61
31251134 2019
112
Inhibition of alpha7 nicotinic receptors in the ventral hippocampus selectively attenuates reinstatement of morphine-conditioned place preference and associated changes in AMPA receptor binding. 61
29667304 2019
113
Modeling the Prescription Opioid Epidemic. 61
31012032 2019
114
Modeling Responses to Peripheral Nerve Stimulation in the Dorsal Horn. 61
31946365 2019
115
Effects of heroin on rat prosocial behavior. 61
29726093 2019
116
Editorial: Prescription for Addiction. 61
31002865 2019
117
Prevalent Misconceptions About Opioid Use Disorders in the United States Produce Failed Policy and Public Health Responses. 61
30452633 2019
118
Synaptic Regulation by OPRM1 Variants in Reward Neurocircuitry. 61
31109961 2019
119
The Social and Functional Implications of High- Versus Low-Dose Opioids on Chronic Non-Cancer Pain. 61
31337176 2019
120
Delivery of bupivacaine from UHMWPE and its implications for managing pain after joint arthroplasty. 61
31173960 2019
121
Decreased Level of Blood MicroRNA-133b in Men with Opioid Use Disorder on Methadone Maintenance Therapy. 61
31349687 2019
122
Morphine-dependent and abstinent mice are characterized by a broader distribution of the neurons co-expressing mu and delta opioid receptors. 61
30858104 2019
123
Opioids in the Management of Acute Pediatric Pain: An Update in a Time of Crisis. 61
30985397 2019
124
[Improve the benefit/risk balance of methadone by respecting its pharmacological specificities]. 61
31178032 2019
125
Endogenous opioid modulation of food intake and body weight: Implications for opioid influences upon motivation and addiction. 61
31047940 2019
126
The Slow-Motion Catastrophe of Antimicrobial Resistance and Practical Interventions for All Prescribers. 61
30922694 2019
127
The prescription opioid crisis: role of the anaesthesiologist in reducing opioid use and misuse. 61
30915988 2019
128
A review of opioid addiction genetics. 61
30118972 2019
129
Opioid addiction. 61
31085190 2019
130
Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction. 61
30729416 2019
131
MicroRNA-132 in the Adult Dentate Gyrus is Involved in Opioid Addiction Via Modifying the Differentiation of Neural Stem Cells. 61
30721395 2019
132
Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities. 61
30786212 2019
133
State of the art opioid-sparing strategies for post-operative pain in adult surgical patients. 61
30810425 2019
134
Physician's role in prescribing opioids in developing countries. 61
31160299 2019
135
Overexpression of miR-9 in the Nucleus Accumbens Increases Oxycodone Self-Administration. 61
30989210 2019
136
7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects. 61
31263758 2019
137
The role of IRAS/Nischarin involved in the development of morphine tolerance and physical dependence. 61
30902386 2019
138
Strategies to Identify Patient Risks of Prescription Opioid Addiction When Initiating Opioids for Pain: A Systematic Review. 61
31050783 2019
139
The projected costs and benefits of a supervised injection facility in Seattle, WA, USA. 61
30802842 2019
140
Acute Opiate Overdose: An Update on Management Strategies in Emergency Department and Critical Care Unit. 61
28952972 2019
141
Time-dependent regional brain distribution of methadone and naltrexone in the treatment of opioid addiction. 61
29441714 2019
142
Selective dopamine D3 receptor antagonist YQA14 inhibits morphine-induced behavioral sensitization in wild type, but not in dopamine D3 receptor knockout mice. 61
30224637 2019
143
Effects of Solvent Vapor Modifiers for the Separation of Opioid Isomers in Micromachined FAIMS-MS. 61
30877655 2019
144
The role of neurologists in tackling the opioid epidemic. 61
30792513 2019
145
Opioid-galanin receptor heteromers differentiate the dopaminergic effects of morphine and methadone. 61
31135380 2019
146
Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone. 61
31120195 2019
147
The active heroin metabolite 6-acetylmorphine has robust reinforcing effects as assessed by self-administration in the rat. 61
30578794 2019
148
Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats. 61
30660628 2019
149
Oxycodone-like discriminative stimulus effects of fentanyl-related emerging drugs of abuse in mice. 61
30735691 2019
150
MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats. 61
30768946 2019
151
Examining Perceived Stress, Childhood Trauma and Interpersonal Trauma in Individuals With Drug Addiction. 61
29569991 2019
152
Cancer Pain Management at Oncology Units: Comparing Knowledge, Attitudes and Perceived Barriers Between Physicians and Nurses. 61
29288475 2019
153
Reduced volumes of the external and internal globus pallidus in male heroin addicts: a postmortem study. 61
30173319 2019
154
Is thrombotic event a side effect of oral buprenorphine abuse? Two case reports. 61
30997076 2019
155
The Patient with Difficult Cancer Pain. 61
31010249 2019
156
Reducing Health-Related Stigma Through Narrative Messages. 61
31014112 2019
157
Current strategies toward safer mu opioid receptor drugs for pain management. 61
30802415 2019
158
Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. 61
29955162 2019
159
VMAT2 gene (SLC18A2) variants associated with a greater risk for developing opioid dependence. 61
30983500 2019
160
Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial. 61
30880163 2019
161
Treating Opioid Dependence: Pain Medicine Physiology of Tolerance and Addiction. 61
30614846 2019
162
Correlates of Opioid Abstinence in a 42-Month Posttreatment Naturalistic Follow-Up Study of Prescription Opioid Dependence. 61
30920187 2019
163
Estimation of the Number of People With Opioid Addiction in Germany. 61
30961791 2019
164
Historical Review: Opiate Addiction and Opioid Receptors. 61
30419763 2019
165
Considerations in addressing the opioid epidemic and chronic pain within the USA. 61
30806566 2019
166
Formation of a morphine-conditioned place preference does not change the size of evoked potentials in the ventral hippocampus-nucleus accumbens projection. 61
30914714 2019
167
Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs. 61
31058214 2019
168
Medicaid Expansion and Prescription Trends: Opioids, Addiction Therapies, and Other Drugs. 61
30629018 2019
169
Potential strategies to combat the opioid crisis. 61
30722706 2019
170
Opioid Prescribing Education for Physician Assistant Students: A Physician Assistant Educator Survey. 61
30720704 2019
171
Treatment for Opioid Addiction Must Be Offered in General Hospitals: But How? 61
30652975 2019
172
Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats. 61
29967454 2019
173
Removal of microglial-specific MyD88 signaling alters dentate gyrus doublecortin and enhances opioid addiction-like behaviors. 61
30447281 2019
174
Opioid addiction: long-acting formulations for a long-term disorder. 61
30792006 2019
175
Opioid Use in Pregnant Women and Neonatal Abstinence Syndrome-A Review of the Literature. 61
30781484 2019
176
Youth and the Opioid Epidemic. 61
30602544 2019
177
Drug-induced prolonged corrected QT interval in patients with methadone and opium overdose. 61
30786894 2019
178
Addressing the Rural Opioid Addiction and Overdose Crisis Through Cross-Sector Collaboration: Little Falls, Minnesota. 61
30571298 2019
179
Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study. 61
30566177 2019
180
Dentate gyrus μ-opioid receptor-mediated neurogenic processes are associated with alterations in morphine self-administration. 61
30728362 2019
181
Reversal of morphine conditioned behavior by an anti-dopaminergic post-trial drug treatment during re-consolidation. 61
30114434 2019
182
Exploring the experiences of staff working at an opiate assisted treatment clinic: An interpretive descriptive study. 61
30683250 2019
183
Transcranial direct current stimulation to prevent and treat surgery-induced opioid dependence: a systematic review. 61
30516441 2019
184
Network Alterations in Comorbid Chronic Pain and Opioid Addiction: An Exploratory Approach. 61
31191279 2019
185
The effects of parental opioid use on the parent-child relationship and children's developmental and behavioral outcomes: a systematic review of published reports. 61
30651753 2019
186
The Use of Naltrexone in Dermatology. Current Evidence and Future Directions. 61
30887922 2019
187
Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review. 61
31133886 2019
188
Is There Less Opioid Abuse in States Where Marijuana Has Been Decriminalized, Either for Medicinal or Recreational Use? A Clin-IQ. 61
31768406 2019
189
Changes in Pharmacists' Perceptions After a Training in Opioid Misuse and Accidental Overdose Prevention. 61
30614959 2019
190
The federal plan for health science and technology's response to the opioid crisis: understanding sex and gender differences as part of the solution is overlooked. 61
30616693 2019
191
Synthetic Opioid Use and Common Injection-associated Viruses: Expanding the Translational Research Agenda. 61
31210115 2019
192
Evidence of Modeling Impact in Development of Policies for Controlling the Opioid Epidemic and Improving Public Health: A Scoping Review. 61
31447562 2019
193
The role of heat shock protein 90 in regulating pain, opioid signaling, and opioid antinociception. 61
31421708 2019
194
Prefrontal-accumbens opioid plasticity: Implications for relapse and dependence. 61
30465850 2019
195
Comparison between intravenous morphine versus fentanyl in acute pain relief in drug abusers with acute limb traumatic injury. 61
30598715 2019
196
The Opioid Epidemic: America's Epidemic. 61
32032071 2019
197
A Mouse Model of Postoperative Pain. 61
30820443 2019
198
OPRM1 A118G Polymorphisms and Its Role in Opioid Addiction: Implication on Severity and Treatment Approaches. 61
31819591 2019
199
Kratom and Future Treatment for the Opioid Addiction and Chronic Pain: Periculo Beneficium? 61
28443503 2019
200
A 3' UTR SNP rs885863, a cis-eQTL for the circadian gene VIPR2 and lincRNA 689, is associated with opioid addiction. 61
31689297 2019
201
The case for a medication first approach to the treatment of opioid use disorder. 61
31084515 2019
202
Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain. 61
31997882 2019
203
Psycho-physiological response to pain among individuals with comorbid pain and opioid use disorder: Implications for patients with prolonged abstinence. 61
31246117 2019
204
The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. 61
29309700 2019
205
Altering Opioid Neuromodulation in the Songbird Basal Ganglia Modulates Vocalizations. 61
31333400 2019
206
Training community-based treatment providers to implement contingency management for opioid addiction: Time to and frequency of adoption. 61
30352667 2018
207
Medication-Assisted Treatment Considerations for Women with Opiate Addiction Disorders. 61
30401353 2018
208
TRPV1 modulates morphine self-administration via activation of the CaMKII-CREB pathway in the nucleus accumbens. 61
30292787 2018
209
Deletion of the type 2 metabotropic glutamate receptor increases heroin abuse vulnerability in transgenic rats. 61
30283001 2018
210
Frontline Science: Buprenorphine decreases CCL2-mediated migration of CD14+ CD16+ monocytes. 61
29791013 2018
211
Addressing the growing opioid and heroin abuse epidemic: a call for medical school curricula. 61
29708863 2018
212
Opiate-Free Tricuspid Valve Replacement: Case Report. 61
29676223 2018
213
Chronic co-administration of nalbuphine attenuates the development of opioid dependence. 61
30312633 2018
214
The risk for problematic opioid use in chronic pain: What can we learn from studies of pain and reward? 61
28778406 2018
215
Perceived Barriers and Facilitators to Providing Methadone Maintenance Treatment Among Rural Community Pharmacists in Southwestern Ontario. 61
28872697 2018
216
Opioid Prescribing Practice and Needs in Thyroid and Parathyroid Surgery. 61
30422170 2018
217
Chronic Oxycodone Self-administration Altered Reward-related Genes in the Ventral and Dorsal Striatum of C57BL/6J Mice: An RNA-seq Analysis. 61
30059705 2018
218
The Emerging Role of Inhaled Heroin in the Opioid Epidemic: A Review. 61
29987325 2018
219
Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone. 61
30695679 2018
220
Commentary: Role of the Endogenous Opiate System in Psychiatric Disorders Other Than Addiction. 61
30395553 2018
221
Pain Reduction with Negative Pressure on Surgical Site Incisions. 61
30276784 2018
222
Sex Differences in the Rat Hippocampal Opioid System After Oxycodone Conditioned Place Preference. 61
30316908 2018
223
Modeling Health Benefits and Harms of Public Policy Responses to the US Opioid Epidemic. 61
30138057 2018
224
The Opioid Crisis and the Certified Registered Nurse Anesthetist: Caring for Patients With Opioid Use Disorder in Drug-Free Recovery. 61
31584414 2018
225
In Memoriam-Honoring the Victims of Opioid Addiction. 61
30304411 2018
226
Pharmacotherapy for opioid addiction in community corrections. 61
30522370 2018
227
Genetic deletion of the dopamine D3 receptor increases vulnerability to heroin in mice. 61
30138692 2018
228
Molecular Genetics and New Medication Strategies for Opioid Addiction. 61
30068261 2018
229
Comparison between buprenorphine provider availability and opioid deaths among US counties. 61
30126537 2018
230
Interventions for Postsurgical Opioid Prescribing: A Systematic Review. 61
30140931 2018
231
Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers. 61
30646222 2018
232
Environmental novelty modulates the induction and expression of single injection-induced behavioral sensitization to morphine. 61
30031027 2018
233
Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications. 61
30248201 2018
234
Opioid Exposure is Associated with Aberrant DNA Methylation of OPRM1 Promoter Region in a Chinese Han Population. 61
29564682 2018
235
Factors underlying risk taking in heroin-dependent individuals: Feedback processing and environmental contingencies. 61
29778626 2018
236
Opioid addiction, opioid addiction treatment, and HIV infection. 61
30384332 2018
237
Diagnosing opioid addiction in people with chronic pain. 61
30242012 2018
238
Craving Behavior from Opioid Addiction Controlled with Olanzapine in an Advanced Cancer Patient: A Case Report. 61
30070936 2018
239
Buprenorphine Provision by Early Career Family Physicians. 61
30201642 2018
240
Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy. 61
30092933 2018
241
Opioid Initiation to Substance Use Treatment: "They Just Want to Feel Normal". 61
30052592 2018
242
Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees. 61
30646185 2018
243
Transcutaneous Electrical Nerve Stimulation (TENS) in the Emergency Department for Pain Relief: A Preliminary Study of Feasibility and Efficacy. 61
30202501 2018
244
Gestational changes in buprenorphine exposure: A physiologically-based pharmacokinetic analysis. 61
29873094 2018
245
A multimodal analgesic protocol may reduce opioid use after third molar surgery: A pilot study. 61
29880285 2018
246
Death Ambivalence and Treatment Seeking: Suicidality in Opiate Addiction. 61
30598866 2018
247
The Evolving Landscape of Acute Pain Management in the Era of the Opioid Crisis. 61
30151792 2018
248
Meting Out Medication, Not Punishment. 61
30142063 2018
249
A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. 61
30158150 2018
250
Neuropsychiatric Lyme Borreliosis: An Overview with a Focus on a Specialty Psychiatrist's Clinical Practice. 61
30149626 2018
251
Cannabis Use is Associated with Lower Odds of Prescription Opioid Analgesic Use Among HIV-Infected Individuals with Chronic Pain. 61
29338578 2018
252
Future development of a depot antiepileptic drug: What are the ethical implications? 61
30032805 2018
253
Implication of OPRM1 A118G Polymorphism in Opioids Addicts in Pakistan: In vitro and In silico Analysis. 61
30033503 2018
254
The 21st Century Cures Act Implications for the Reduction of Racial Health Disparities in the US Criminal Justice System: a Public Health Approach. 61
29124683 2018
255
Predictors of craving and substance use among patients with alcohol, tobacco, cannabis or opiate addictions: Commonalities and specificities across substances. 61
29428330 2018
256
Psychological features of abstinent heroin users before and after rehabilitation in Saint Petersburg, Russia. 61
30107818 2018
257
Positive reinforcement targeting abstinence in substance misuse (PRAISe): Study protocol for a Cluster RCT & process evaluation of contingency management. 61
29908336 2018
258
Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015. 61
29734918 2018
259
Rural Postpartum Women With Substance Use Disorders. 61
29651928 2018
260
Oxytocin and opioid addiction revisited: old drug, new applications. 61
28378414 2018
261
Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine. 61
29608409 2018
262
AMPA receptor positive allosteric modulators attenuate morphine tolerance and dependence. 61
29751227 2018
263
National Institute on Drug Abuse International Program: improving opioid use disorder treatment through international research training. 61
29771745 2018
264
Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy. 61
29950444 2018
265
Curbing opioid addiction needs more than new drugs. 61
29921860 2018
266
Buprenorphine Supply, Access, and Quality: Where We Have Come and the Path Forward. 61
30147002 2018
267
For Whom the Bell Tolls: A Special Journal Issue on Smoking Control and an Interview With Dr Harry Lando. 61
29893140 2018
268
Natural Language Processing-Identified Problem Opioid Use and Its Associated Health Care Costs. 61
30702378 2018
269
Opioid addiction, diversion, and abuse in chronic and cancer pain. 61
29465470 2018
270
Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C. 61
29796965 2018
271
Expression of NMDA receptor subunits in human blood lymphocytes: A peripheral biomarker in online computer game addiction. 61
29788757 2018
272
Invited Commentary: A Novel Strategy for Addressing Unmeasured Confounding When Comparing Opioid Agonist Therapies in Pregnancy. 61
29155916 2018
273
Student pharmacist perceptions of participation in hands-on naloxone counseling. 61
30025770 2018
274
Fear Memory Recall Potentiates Opiate Reward Sensitivity through Dissociable Dopamine D1 versus D4 Receptor-Dependent Memory Mechanisms in the Prefrontal Cortex. 61
29686048 2018
275
Substance Abuse and Addiction: Implications for Early Relationships and Interventions. 61
30662145 2018
276
Barriers and Facilitators of Breastfeeding Reported by Postpartum Women in Methadone Maintenance Therapy. 61
29595995 2018
277
Opioid Stewardship in Otolaryngology: State of the Art Review. 61
29437536 2018
278
Use of epidural clonidine for the management of analgesia in the opioid addicted parturient on buprenorphine maintenance therapy: an observational study. 61
29486974 2018
279
Acupuncture and the Opioid Epidemic in America. 61
29752610 2018
280
Ethical Issues in Research Involving Participants With Opioid Use Disorder. 61
29714588 2018
281
The Neurobiology of Opioid Addiction and the Potential for Prevention Strategies. 61
29710202 2018
282
Emergency Department Treatment of Opioid Addiction: An Opportunity to Lead. 61
29266577 2018
283
Regulator of G-Protein Signaling 4 (RGS4) Controls Morphine Reward by Glutamate Receptor Activation in the Nucleus Accumbens of Mouse Brain. 61
29754475 2018
284
Canine-assisted Therapy as an Adjunct Tool in the Care of the Surgical Patient: A Literature Review and Opportunity for Research. 61
29477136 2018
285
Trends in Medical Use of Opioids in the U.S., 2006-2016. 61
29551331 2018
286
A Novel Role for Oligodendrocyte Precursor Cells (OPCs) and Sox10 in Mediating Cellular and Behavioral Responses to Heroin. 61
29260792 2018
287
Dynamic lateral organization of opioid receptors (kappa, muwt and muN40D ) in the plasma membrane at the nanoscale level. 61
29808515 2018
288
Quality of life comparison between smokers and non-smokers with chronic pancreatitis. 61
29500114 2018
289
Antagonist treatment is just as effective as replacement therapy for opioid addiction but neither is used often enough. 61
29676241 2018
290
Opioid Deaths Among Women Not Getting the Attention They Warrant. 61
29701581 2018
291
Morphine in Plasma and Cerebrospinal Fluid of Patients Addicted to Opiates Undergoing Surgery: High-performance Liquid Chromatography Method. 61
31069033 2018
292
The opioid crisis: a 21st century pain. 61
29869649 2018
293
Evidence for differential opioid use disorder in schizophrenia in an addiction treatment population. 61
28487076 2018
294
Total hypothalamic volume is reduced in postmortem brains of male heroin addicts. 61
28534187 2018
295
Opioid use and stigma: The role of gender, language and precipitating events. 61
29499554 2018
296
Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail. 61
29623562 2018
297
Payer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio. 61
29176511 2018
298
Role of mGlu7 receptor in morphine rewarding effects is uncovered by a novel orthosteric agonist. 61
29307544 2018
299
Survey Assessing Medical Student and Physician Knowledge and Attitudes Regarding the Opioid Crisis. 61
29677413 2018
300
Locomotor activity does not predict individual differences in morphine self-administration in rats. 61
29409807 2018
301
Tackling an Epidemic: New and Emerging Opioid Addiction Treatments Offer Hope for Solutions to This Crisis. 61
29553937 2018
302
Medication development in opioid addiction: Meaningful clinical end points. 61
29593105 2018
303
Opioid Receptors Gene Polymorphism and Heroin Dependence in Iran. 61
29967669 2018
304
Compulsive-Like Sufentanil Vapor Self-Administration in Rats. 61
28812595 2018
305
Suboptimal Opioid Prescribing: A Practice Change Project. 61
29490325 2018
306
Home-based delivery of XR-NTX in youth with opioid addiction. 61
28867062 2018
307
The effect of state laws designed to prevent nonmedical prescription opioid use on overdose deaths and treatment. 61
28719096 2018
308
Potential role for acupuncture in the treatment of food addiction and obesity. 61
29223953 2018
309
An analysis of genetic association in opioid dependence susceptibility. 61
28656735 2018
310
Cognitive effects of labeled addictolytic medications. 61
28919445 2018
311
Impact of opioid therapy on gonadal hormones: focus on buprenorphine. 61
29453925 2018
312
Cannabis use moderates the relationship between pain and negative affect in adults with opioid use disorder. 61
29078148 2018
313
Mindfulness-based interventions for chronic pain: Evidence and applications. 61
29220782 2018
314
Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation. 61
29158248 2018
315
The Clinical Concept of Opioid Addiction Since 1877: Still Wanting After All These Years. 61
30386269 2018
316
Opioid addiction and borderline personality disorder. 61
29283477 2018
317
Pulmonary artery intravascular abscess: A rare complication of incomplete infective endocarditis treatment in the setting of injection drug use. 61
29942758 2018
318
Medication-Assisted Treatment (MAT) for Opioid Addiction: Introduction to the Special Issue. 61
29220615 2018
319
A computational strategy for finding novel targets and therapeutic compounds for opioid dependence. 61
30403753 2018
320
Opioid Use by Patients After Rhinoplasty. 61
29121158 2018
321
A randomized matched-pairs study of feasibility, acceptability, and effectiveness of systems consultation: a novel implementation strategy for adopting clinical guidelines for Opioid prescribing in primary care. 61
29370813 2018
322
Dopamine gene variants in opioid addiction: comparison of dependent patients, nondependent users and healthy controls. 61
29210332 2018
323
The Benefits of Genetic Addiction Risk Score (GARS™) Testing in Substance Use Disorder (SUD). 61
30198022 2018
324
Fentanyl and the Evolving Opioid Epidemic: What Strategies Should Policy Makers Consider? 61
28967324 2018
325
From Narcotic to Normalizer: The Misperception of Methadone Treatment and the Persistence of Prejudice and Bias. 61
29236562 2018
326
A Tale of Two Knee Implants in the Same Person: Narcotics for the First and Anti-inflammatory Drugs for the Second. 61
30158828 2018
327
Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary. 61
28862903 2018
328
A public health approach to opioid addiction in North America - Author's reply. 61
30277884 2018
329
Intolerance of uncertainty and conditioned place preference in opioid addiction. 61
29844956 2018
330
Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine. 61
30713510 2018
331
Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals. 61
28247526 2018
332
Opioid Addiction in Pregnancy: Does Depression Negatively Impact Adherence With Prenatal Care? 61
29068826 2018
333
A public health approach to opioid addiction in North America. 61
30277881 2018
334
Oxycodone Self-Administration Induces Alterations in Expression of Integrin, Semaphorin and Ephrin Genes in the Mouse Striatum. 61
29946272 2018
335
Social Influences in Animal Models of Opiate Addiction. 61
30193710 2018
336
Changing the Treatment Direction for Opiate Addiction: Dr. Dole's Research. 61
29227710 2018
337
Robust age, but limited sex, differences in mu-opioid receptors in the rat brain: relevance for reward and drug-seeking behaviors in juveniles. 61
28871491 2018
338
Impacts of GRIN3A, GRM6 and TPH2 genetic polymorphisms on quality of life in methadone maintenance therapy population. 61
30059533 2018
339
Overcoming medication stigma in peer recovery: A new paradigm. 61
29432086 2018
340
OPRD1 Genetic Variation and Human Disease. 61
28035534 2018
341
A Surging Drug Epidemic: Time for Congress to Enact a Mandate on Insurance Companies and Rehabilitation Facilities for Opioid and Opiate Addiction. 61
30889332 2018
342
Psychopathology of addiction: Can the SCL90-based five-dimensional structure differentiate Heroin Use Disorder from a non-substance-related addictive disorder such as Gambling Disorder? 61
29371875 2018
343
Opioid addiction: Who are your real friends? 61
28552458 2017
344
Support for Treating Opioid Addiction With Medication. 61
29209706 2017
345
Screening in Trauma for Opioid Misuse Prevention (STOMP): study protocol for the development of an opioid risk screening tool for victims of injury. 61
29198186 2017
346
Prescribing Opioid Replacement Therapy in U.S. Correctional Settings. 61
29282239 2017
347
Pain management strategies for patients on methadone maintenance therapy: a systematic review of the literature. 61
27566722 2017
348
Special indications for Opioid Free Anaesthesia and Analgesia, patient and procedure related: Including obesity, sleep apnoea, chronic obstructive pulmonary disease, complex regional pain syndromes, opioid addiction and cancer surgery. 61
29739543 2017
349
Risk factors for addiction among patients receiving prescribed opioids: a systematic review protocol. 61
29282114 2017
350
Social networking online to recover from opioid use disorder: A study of community interactions. 61
29024875 2017
351
The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats. 61
28888944 2017
352
The Opioid Crisis in Missouri: A Call to Action for Physicians, Legislators, and Society. 61
30228662 2017
353
Temporal effect of manipulating NeuroD1 expression with the synthetic small molecule KHS101 on morphine contextual memory. 61
28842345 2017
354
Behavioral and transcriptional patterns of protracted opioid self-administration in mice. 61
27578564 2017
355
Leptin status alters buprenorphine-induced antinociception in obese mice with dysfunctional leptin receptors. 61
28893589 2017
356
Src-dependent phosphorylation of μ-opioid receptor at Tyr336 modulates opiate withdrawal. 61
28818835 2017
357
Evidence for GABA-A receptor dysregulation in gambling disorder: correlation with impulsivity. 61
27739164 2017
358
Ghrelin receptor antagonism of morphine-induced conditioned place preference and behavioral and accumbens dopaminergic sensitization in rats. 61
28958601 2017
359
Neuroprotective effect of Bacopa monnieri against morphine-induced histopathological changes in the cerebellum of rats. 61
29175775 2017
360
Buprenorphine augmentation improved symptoms of OCD, compared to placebo - Results from a randomized, double-blind and placebo-controlled clinical trial. 61
28647677 2017
361
Nutritional Factors Affecting Adult Neurogenesis and Cognitive Function. 61
29141966 2017
362
Managing Opioid Addiction Risk in Plastic Surgery during the Perioperative Period. 61
28953743 2017
363
How inappropriate prescribing prompted the opioid addiction ravaging small town America. 61
29051156 2017
364
Ten Steps the Federal Government Should Take Now to Reverse the Opioid Addiction Epidemic. 61
29049522 2017
365
A Call for Compassionate Care. 61
29200050 2017
366
Craving and Drug Reward: A Comparison of Celecoxib and Ibuprofen in Detoxifying Opiate Addicts. 61
29472948 2017
367
Association of OPRK1 gene polymorphisms with opioid dependence in addicted men undergoing methadone treatment in an Iranian population. 61
28786760 2017
368
Pain management in rheumatology research, training, and practice. 61
28967362 2017
369
Contingency management for tobacco smoking during opioid addiction treatment: a randomised pilot study. 61
28864706 2017
370
Trait Mindfulness and Progression to Injection Use in Youth With Opioid Addiction. 61
28471275 2017
371
Association of the Five-Factor Model personality traits and opioid addiction treatment outcome. 61
28953780 2017
372
Mitragyna speciosa: Balancing Potential Medical Benefits and Abuse. 61
28947930 2017
373
Pharmacoepigenomics of opiates and methadone maintenance treatment: current data and perspectives. 61
28841113 2017
374
A brief review of the genetics and pharmacogenetics of opioid use disorders. 61
29302220 2017
375
Nortriptyline Enhances Morphine-Conditioned Place Preference in Neuropathic Rats: Role of the Central Noradrenergic System. 61
28537967 2017
376
A systematic overview of the literature regarding group prenatal care for high-risk pregnant women. 61
28962601 2017
377
TRPV1 modulates morphine-induced conditioned place preference via p38 MAPK in the nucleus accumbens. 61
28734766 2017
378
Role of olfactory reactions, nociception, and immunoendocrine shifts in addictive disorders. 61
28782904 2017
379
Contingency Management interventions for non-prescribed drug use during treatment for opiate addiction: A systematic review and meta-analysis. 61
28688295 2017
380
Opiates and Plasticity in the Ventral Tegmental Area. 61
28768409 2017
381
Multi-variant Genetic Panel for Genetic Risk of Opioid Addiction. 61
28801372 2017
382
Buprenorphine implants in medical treatment of opioid addiction. 61
28571505 2017
383
Quantifying absolute glutamate concentrations in nucleus accumbens of prescription opioid addicts by using 1H MRS. 61
28828225 2017
384
Introduction: The specter of opiate addiction in reproductive medicine. 61
28697914 2017
385
High-Frequency Stimulation of the Subthalamic Nucleus Blocks Compulsive-Like Re-Escalation of Heroin Taking in Rats. 61
27917870 2017
386
Effects of alkaloid-rich extract from Mitragyna speciosa (Korth.) Havil. on naloxone-precipitated morphine withdrawal symptoms and local field potential in the nucleus accumbens of mice. 61
28687506 2017
387
Recent incarceration and buprenorphine maintenance treatment outcomes among human immunodeficiency virus-positive patients. 61
27715904 2017
388
Battling the biology of opioid addiction. 61
28697181 2017
389
Methadone Treatment of Opiate Addiction: A Systematic Review of Comparative Studies. 61
29616150 2017
390
Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction. 61
28164407 2017
391
Denial: The Greatest Barrier to the Opioid Epidemic. 61
28694276 2017
392
The Role of Dopamine D1 and D3 Receptors in N-Methyl-D-Aspartate (NMDA)/GlycineB Site-Regulated Complex Cognitive Behaviors following Repeated Morphine Administration. 61
28199666 2017
393
Positive association of personal distress with testosterone in opiate-addicted patients. 61
28281909 2017
394
Mindfulness-Based Relapse Prevention for Methadone Maintenance: A Feasibility Trial. 61
28488881 2017
395
Fate of Medicaid expansion rests with senators from drug-torn states. 61
30481411 2017
396
Coping with the enduring unpredictability of opioid addiction: An investigation of a novel family-focused peer-support organization. 61
28222927 2017
397
Opioid addiction and misuse in adult and adolescent patients with cancer. 61
28580748 2017
398
Five sentence letter from 1980 helped create US opioid addiction crisis, study concludes. 61
28588040 2017
399
A 1980 Letter on the Risk of Opioid Addiction. 61
28564561 2017
400
A comparison of bone quality and its determinants in young opioid-dependent women with healthy control group. 61
28458076 2017
401
Maternal-Fetal Monitoring of Opioid-Exposed Pregnancies: Analysis of a Pilot Community-Based Protocol and Review of the Literature. 61
28363609 2017
402
Rapid Identification of Buprenorphine in Patient Saliva. 61
28944090 2017
403
Synthesis and evaluation of a ligand targeting the μ and δ opioid receptors for drug delivery to lung cancer. 61
28291693 2017
404
Use and misuse of opioid agonists in opioid addiction. 61
28530896 2017
405
A false start in the fight against opioid addiction. 61
30475467 2017
406
An Osteopathic Approach to Chronic Pain Management. 61
28459476 2017
407
Making the Choices Necessary to Make a Difference: The Responsibility of National Bioethics Commissions. 61
28543648 2017
408
Illustrating and analyzing the processes of multi-institutional collaboration: Lessons learnt at Howard University Hospital. 61
28966991 2017
409
Genetic variation in the behavioral effects of buprenorphine in female mice derived from a murine model of the OPRM1 A118G polymorphism. 61
28188737 2017
410
Porous silicon mass spectrometry as an alternative confirmatory assay for compliance testing of methadone. 61
27364015 2017
411
Putting a face to opiate addiction for students at a needle exchange programme. 61
28394056 2017
412
P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine. 61
28111265 2017
413
Prescription opioid addiction and chronic pain: More than a feeling. 61
28363323 2017
414
The Prescription Opioid Addiction Treatment Study: What have we learned. 61
28363320 2017
415
Opiate addiction and overdose: experiences, attitudes, and appetite for community naloxone provision. 61
28246098 2017
416
Proceedings from Bridging Health Disparities to Address the Opioid Epidemic: A Symposium at the Warren Alpert Medical School of Brown University. 61
28375414 2017
417
The mask of acute bacterial pneumonia may disguise the face of tuberculosis. 61
28461868 2017
418
Spiritual Well-Being and Associated Factors with Relapse in Opioid Addicts. 61
28511485 2017
419
Opioid Use for Pain Management After Implementation of a Medicaid Short-Acting Opioid Quantity Limit. 61
28230448 2017
420
Probuphine® (buprenorphine implant): a promising candidate in opioid dependence. 61
28348732 2017
421
Five-Factor Model Personality Profiles: The Differences between Alcohol and Opiate Addiction among Females. 61
28291977 2017
422
When doctors are patients: a narrative study of help-seeking behaviour among addicted physicians. 61
27587488 2017
423
Current Concepts in Methadone Metabolism and Transport. 61
28263461 2017
424
Treatment Outcome Comparison Between Telepsychiatry and Face-to-face Buprenorphine Medication-assisted Treatment for Opioid Use Disorder: A 2-Year Retrospective Data Analysis. 61
28107210 2017
425
Overdose Risk in Young Children of Women Prescribed Opioids. 61
28219963 2017
426
The association between age of onset of opioid use and comorbidity among opioid dependent patients receiving methadone maintenance therapy. 61
28347350 2017
427
Oxycodone self-administration in male and female rats. 61
28127624 2017
428
How States Are Tackling the Opioid Crisis. 61
28152337 2017
429
Irish GPs support wider use of naloxone to treat opiate addiction. 61
28258095 2017
430
Pearls and pitfalls for prescribing opioids in a climate of increased provider scrutiny. 61
28792290 2017
431
Mortality related to methadone maintenance treatment in Stockholm, Sweden, during 2006-2013. 61
28132698 2017
432
Pharmacologic Treatment of Opioid Addiction During Pregnancy. 61
28187838 2017
433
Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study. 61
28209683 2017
434
Something for pain: Responsible opioid use in emergency medicine. 61
27802876 2017
435
A precision medicine approach to a patient with unresolved pain following orthopedic surgery: a case report. 61
28231802 2017
436
Transgenerational attenuation of opioid self-administration as a consequence of adolescent morphine exposure. 61
27729240 2017
437
Systemic and individual factors in the buprenorphine treatment-seeking process: a qualitative study. 61
28086837 2017
438
New developments in managing opioid addiction: impact of a subdermal buprenorphine implant. 61
28546740 2017
439
Acute Morphine, Chronic Morphine, and Morphine Withdrawal Differently Affect Pleiotrophin, Midkine, and Receptor Protein Tyrosine Phosphatase β/ζ Regulation in the Ventral Tegmental Area. 61
26742526 2017
440
Intolerance of uncertainty in opioid dependency - Relationship with trait anxiety and impulsivity. 61
28759635 2017
441
The Impact of Saffron on Symptoms of Withdrawal Syndrome in Patients Undergoing Maintenance Treatment for Opioid Addiction in Sabzevar Parish in 2017. 61
29359178 2017
442
Validated Spectrophtometric Method for Simultaneous Determination of Buprenorphine and Naloxone in Pharmaceutical Dosage Forms. 61
28496466 2017
443
Opioid Addiction: Social Problems Associated and Implications of Both Current and Possible Future Treatments, including Polymeric Therapeutics for Giving Up the Habit of Opioid Consumption. 61
28607934 2017
444
Opioid Addiction and Implications for Employers. 61
29465184 2017
445
Learning and generalization from reward and punishment in opioid addiction. 61
27641323 2017
446
Assessing Differences in the Availability of Opioid Addiction Therapy Options: Rural Versus Urban and American Indian Reservation Versus Nonreservation. 61
26987797 2017
447
Loperamide Abuse Associated With Cardiac Dysrhythmia and Death. 61
27140747 2017
448
Nurse Practitioner Prescriptive Authority for Buprenorphine: From DATA 2000 to CARA 2016. 61
28252511 2017
449
'Americans are safer and healthier today than they were in 2009'. 61
30645799 2017
450
Knowledge and stigma regarding methadone maintenance treatment among personnel of methadone maintenance treatment and non-methadone maintenance treatment addiction facilities in Israel. 61
27636020 2017
451
Intranasal naloxone and related strategies for opioid overdose intervention by nonmedical personnel: a review. 61
29066940 2017
452
Traditional Chinese Medicine (TCM) Therapy. 61
29098677 2017
453
The Effects of Perinatal Oxycodone Exposure on Behavioral Outcome in a Rodent Model. 61
28971091 2017
454
The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research. 61
27356522 2017
455
Agmatine Prevents Adaptation of the Hippocampal Glutamate System in Chronic Morphine-Treated Rats. 61
27161447 2016
456
Alcohol use in opioid agonist treatment. 61
27931253 2016
457
Disciplining virtue: investigating the discourses of opioid addiction in nursing. 61
27605201 2016
458
People Control Their Addictions: No matter how much the "chronic" brain disease model of addiction indicates otherwise, we know that people can quit addictions - with special reference to harm reduction and mindfulness. 61
29511729 2016
459
The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial. 61
27955689 2016
460
Abuse of Gabapentin is Associated with Opioid Addiction. 61
26887855 2016
461
Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. 61
27286724 2016
462
The War on Drugs That Wasn't: Wasted Whiteness, "Dirty Doctors," and Race in Media Coverage of Prescription Opioid Misuse. 61
27272904 2016
463
Blockade of dorsal hippocampal orexin-1 receptors impaired morphine-induced state-dependent learning. 61
27751532 2016
464
Heantos-4, a natural plant extract used in the treatment of drug addiction, modulates T-type calcium channels and thalamocortical burst-firing. 61
27919294 2016
465
Opioid Addiction in Adolescents: A Background and Policy Brief. 61
27666505 2016
466
NF1 Is a Direct G Protein Effector Essential for Opioid Signaling to Ras in the Striatum. 61
27773571 2016
467
A mechanistic approach to modelling the formation of a drug reservoir in the skin. 61
27592115 2016
468
Experience of the use of Ketamine to manage opioid withdrawal in an addicted woman: a case report. 61
27832755 2016
469
Bidirectional Modulation of Extinction of Drug Seeking by Deep Brain Stimulation of the Ventral Striatum. 61
27449798 2016
470
Acquisition of morphine conditioned place preference increases the dendritic complexity of nucleus accumbens core neurons. 61
26096355 2016
471
A Second Look at ED-initiated Buprenorphine for Opioid Addiction. 61
29787643 2016
472
Prescription drug monitoring program data tracking of opioid addiction treatment outcomes in integrated dual diagnosis care involving injectable naltrexone. 61
27647699 2016
473
Online resources for opioid addiction. 61
27654447 2016
474
The ABCB1, rs9282564, AG and TT Genotypes and the COMT, rs4680, AA Genotype are Less Frequent in Deceased Patients with Opioid Addiction than in Living Patients with Opioid Addiction. 61
27061230 2016
475
T394A Mutation at the μ Opioid Receptor Blocks Opioid Tolerance and Increases Vulnerability to Heroin Self-Administration in Mice. 61
27707973 2016
476
Evaluation of CART peptide level in rat plasma and CSF: Possible role as a biomarker in opioid addiction. 61
27349817 2016
477
Combined Interactions with I1-, I2-Imidazoline Binding Sites and α2-Adrenoceptors To Manage Opioid Addiction. 61
27774136 2016
478
Functional modulation on macrophage by low dose naltrexone (LDN). 61
27561742 2016
479
Individual differences in initial morphine sensitivity as a predictor for the development of opiate addiction in rats. 61
27457135 2016
480
[Investigation of the medical and social situation of patients managed by opiate replacement regimens for over 10 years by their GP]. 61
27203162 2016
481
Effects of drugs of abuse on hippocampal plasticity and hippocampus-dependent learning and memory: contributions to development and maintenance of addiction. 61
27634143 2016
482
Sexual Abuse and its Relation to Chronic Pain among Women from a Methadone Maintenance Clinic versus a Sexual Abuse Treatment Center. 61
27430532 2016
483
Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience. 61
26508767 2016
484
Active approach works best for battling opioid addiction among clinicians. 61
30005496 2016
485
Community health centers using innovation to address the opioid addiction epidemic. 61
30480887 2016
486
A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here. 61
27008037 2016
487
Morphine addiction in ants: a new model for self-administration and neurochemical analysis. 61
27655824 2016
488
Medication-Assisted Treatment of Adolescents With Opioid Use Disorders. 61
27550978 2016
489
Shifting blame: Buprenorphine prescribers, addiction treatment, and prescription monitoring in middle-class America. 61
27488225 2016
490
The Shelby Clinic Medication-Assisted Treatment for Opioid Addiction. 61
30047628 2016
491
[Understanding Opioid-induced Adverse Effects and its Managements]. 61
30358300 2016
492
ADHD risk alleles associated with opiate addiction: study of addicted parents and their children. 61
27064247 2016
493
Yiguanjian cataplasm attenuates opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome. 61
28459510 2016
494
Impact of Medication-Assisted Treatment for Opioid Addiction on Medicaid Expenditures and Health Services Utilization Rates in Vermont. 61
27296656 2016
495
The Significance of Harm Reduction as a Social and Health Care Intervention for Injecting Drug Users: An Exploratory Study of a Needle Exchange Program in Fresno, California. 61
27167664 2016
496
Opioid Use Disorder in Pregnancy: Health Policy and Practice in the Midst of an Epidemic. 61
27275812 2016
497
Quantitative EEG and Low-Resolution Electromagnetic Tomography (LORETA) Imaging of Patients Undergoing Methadone Treatment for Opiate Addiction. 61
26002855 2016
498
The effect of chronic morphine or methadone exposure and withdrawal on clock gene expression in the rat suprachiasmatic nucleus and AA-NAT activity in the pineal gland. 61
27070740 2016
499
Battling Opioid Addiction. 61
29544043 2016
500
Relapse prevention medications in community treatment for young adults with opioid addiction. 61
26820059 2016
501
When Added to Opioid Agonist Treatment, Psychosocial Interventions do not Further Reduce the Use of Illicit Opioids: A Comment on Dugosh et al. 61
27471920 2016
502
Emotional Impairment and Persistent Upregulation of mGlu5 Receptor following Morphine Abstinence: Implications of an mGlu5-MOPr Interaction. 61
26861145 2016
503
The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and Ways Forward to Promote Retention in Treatment. 61
27211995 2016
504
Impact of a methadone maintenance program on an Aboriginal community: a qualitative study. 61
27730106 2016
505
Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment. 61
26927578 2016
506
Acupuncture for Detoxification in Treatment of Opioid Addiction. 61
27377488 2016
507
Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers. 61
26552847 2016
508
CART peptide and opioid addiction: Expression changes in male rat brain. 61
26955782 2016
509
How to overcome hurdles in opiate substitution treatment? A qualitative study with general practitioners in Belgium. 61
26799738 2016
510
Simultaneous quantification of buprenorphine, naloxone and phase I and II metabolites in plasma and breastmilk by liquid chromatography-tandem mass spectrometry. 61
27083254 2016
511
Using [(11)C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism. 61
26876472 2016
512
Increased intravenous morphine self-administration following Roux-en-Y gastric bypass in dietary obese rats. 61
26304761 2016
513
Nucleus Accumbens AMPA Receptors Are Necessary for Morphine-Withdrawal-Induced Negative-Affective States in Rats. 61
27225765 2016
514
Responding to America's Iatrogenic Epidemic of Prescription Opioid Addiction and Overdose. 61